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ABSTRACT
Traumatic brain injuries (TBI) result in impaired motor and sensory skills, which
amplify over time due to the natural immune responses to trauma. Currently, there is no
therapeutic on the market to treat the secondary damage from the cascading events
caused by neurotrauma. In an experimental treatment method, poly(lactide-co-glycolide)graft-polyethenimine (PgP) is used as a vector for drug delivery. This previously
described method has successfully treated experimental spinal cord injury (SCI) using the
nanoparticles for Rolipram (Rm) delivery, a phosphodiesterase inhibitor, to repair
damage in a rat model. We proposed to utilize this same treatment to reduce secondary
axonal damage after TBI.
A direct injection, used for the experimental treatment of SCI, can cause
additional damage to the neural tissue after diffuse TBI; thus, it is not an efficient method
of administration of therapeutics for a diffuse injury. The noninvasive use of intranasal
(IN) and intravenous (IV) administration would avoid additional injury. Yet, IN and IV
administration of PgP complexed with Rm (PgP-Rm) has not been attempted. This work
shows that IN and IV methods effectively deliver PgP to the brain. That administration of
PgP-Rm via these noninvasive delivery methods reduced secondary damage, resulting in
reduced astroglia activation in the caudate-putamen.
Lastly, a surgical optimization was performed using a new Alcorix silicon-based
shank probe for in vivo glutamate (GLU) recording. The use of implantable biosensors is
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of interest to allow the study of neurotransmitter activity in vivo, after TBI. Surgical
optimization of the new probe led to the reinforcement of the junction between the shank
and mounting board and incorporating a surgically mounted capsule to protect the
probe’s reference wire. This optimized protocol resulted in a successful recording of
GLU with sub-second resolution. This method can be utilized for future implant
surgeries.
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CHAPTER 1
INTRODUCTION
1.1

Background

An estimated 5.3 million Americans are living with traumatic brain injury (TBI)
related disabilities.1,2 Currently, there is no currently approved medication for the
treatment of TBI. Patients suffering from TBI face impaired motor, sensory, and
cognitive skills from either the primary or secondary injury.1,3 The primary injury results
from the sheer force of impact on the neural tissue causing damage to neurons such as
contusion, damage to the vasculature, axonal shearing, and damage to the blood-brain
barrier (BBB).3 The resultant biochemical disruption in the environment causes
secondary injury, characterized by inflammation, disruption of the BBB, ischemia,
depolarization, excitotoxicity, and the generation of free radicals.3,4 The extent of the
secondary injury typically correlates to the prognosis and mortality rate.3
Recently, research has focused on targeting secondary injury for the treatment of
TBI. This method of treatment focuses on limiting the cascading damage of the
secondary injury and reducing further deficits. Rolipram (Rm), which was on the market
as an antidepressant drug, has recently been investigated in neuroscience for its antiinflammatory properties.5–7 Rm functions as a phosphodiesterase IV (PDE4) inhibitor to
increase levels of cyclic AMP in the brain and thereby cause a neuroprotective
transcriptional response (later explained in depth).6,7 In previously performed research,
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Rm showed decreased secondary injury damage by suppressing PDE4 in spinal cord
injury (SCI).4,5,7–9
One major issue of using Rm as a treatment is the severe side effect of extreme
nausea and gastrointestinal distress. One solution is to use a lower concentration with a
directed drug delivery system to bypass the oral consumption of the drug. Poly(lactideco-glycolide)-graft-polyethylenimine (PgP) was developed as a biomedical engineering
solution. This polymeric amphiphilic micelle was developed to target neural cells capable
of carrying the gene and drug load.4,10–12 The PgP nanoparticles consist of a hydrophilic
shell and a hydrophobic core. They have been proven to retain a hydrophobic drug for up
to 5-weeks.4,11 PgP loaded with Rm has been proved to have neuroprotective abilities in
rats when treating SCI.4
The following chapters elucidate the use of this method to treat moderate TBI in
mouse models. Chapter 3 delves into the functional properties of the PgP particles
entering the brain, which established the capability of the nanoparticles to enter through
the blood-brain barrier and move across the various cell types of the brain and remain in
the brain for some time. The research in Chapter 4 delves into the evaluation of
combination drug trials. Minocycline, previously shown to decrease the development of
varicosities due to secondary damage, was used in combination with the PgP-Rm
treatment.13 The effect of minocycline, typically not visualized until 7-days post-injury,
was combined with the fast-acting PgP-Rm for an overall decrease in neurotrauma over
time. As seen in Chapter 4, these evaluations are based on behavioral tests and
immunohistochemistry (IHC) staining.
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In Chapter 5, a new generation of in vivo biosensors (provided by Alcorix and
coated by the Arumugam lab at LA Tech) for real-time recording of glutamate (GLU)
was tested in vivo.14 The surgical implant protocol was optimized for implanting the
probe in rat brains. The result showed sub-second resolution of GLU levels in an awake,
free-moving rat. Secondary damage from TBI can cause excitotoxicity which can consist
of random firing of neurons. By incorporating real-time neurotransmitter analysis, a
therapeutic effect on excitotoxicity can be analyzed.
1.2

Research Objective

This project aims to understand neurotrauma further and evaluate methods for
treating traumatic brain injury (TBI). This understanding may be accomplished by
quantifying the following aims:
1.

Evaluate nanoparticle delivery of therapeutics to treat TBI
a. Determine if poly(lactide-co-glycolide)-graft-polyethylenimine (PgP)
nanoparticles (NP) can penetrate the blood-brain barrier (BBB) and diffuse
through the brain
b. Measure competency of experimental PgP vector for potential drug
delivery
c. Identify the most efficient administration route of PgP to deliver drugs for
TBI treatment

2.

Evaluate combination drug therapy for use in treating TBI
a. Combine nanoparticle treatment with the treatment of a high therapeutic
dose of minocycline
b. Determination of neurological impairments by use of behavioral test
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c. Determine molecular and cellular reaction to treatment and injury
3.

Determine the validity of the new generation of GLU and GABA probe
a. Optimize implant surgery for new silicone shank probe
b. Record GABA/Glut with a calibration curve.

CHAPTER 2
BACKGROUND
2.1
2.1.1

Traumatic Brain Injury (TBI)

Traumatic Brain Injury: The Problem
In the United States, hospitals report about 2.8 million instances of TBI-related

cases each year.1 Furthermore, an estimated 5.3 million Americans are living with TBIrelated disabilities.1,2 These injuries result in impaired motor, sensory and cognitive
skills. TBI is distinguished by the resultant primary and secondary injuries (see Figure
2-1).1,3 The primary injury results from the sheer mechanical force of an impact on neural
tissue, which causes damage to neurons via contusion, damage to the vasculature, axonal
shearing, and damage to the BBB.3 This can create hemorrhage, hematoma, edema, and
herniation of the brain. A deficit in regenerative abilities of neurons coupled with the
biochemical reaction from cells damaged by impact causes the sequelae of secondary
damage. Secondary damage from TBI is characterized by inflammation, disruption of the
BBB, ischemia, depolarization, excitotoxicity, and the generation of free radicals.3,4 This
resultant biochemical shift causes impairments such as loss of long and short-term
memory, motor skills deterioration, deterioration in sensory skills, and a shift in the
psychological state.2,15
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The prognosis and mortality rate of a human post-injury is formally determined by the
extent of the secondary injury, symptoms of which can arise from minutes to years after
the initial injury.3

Figure 2-1: Overview of the damages from TBI. TBI is the result of forces acting on the
neural tissue. The primary injury is a direct effect of those forces and is characterized by
contusions, damage to the vasculature, axonal damage, and damage to the BBB. These
physical damages are exacerbated by continued insult to the brain in the form of
inflammation, ischemia, excitotoxicity, and the interaction of free radicals. This is termed
the secondary injury and continues to affect the brain long after the primary injury is
complete. A combined effect from the physically damaged tissue and the inflammatory
response can lead to axonal degeneration, demyelination, and apoptosis. These issues are
expressed by the significant deficits in sensory, motor, and cognitive impairments seen in
TBI patients.
TBI is the result of forces acting on the neural tissue. The primary injury is a
direct effect of those forces. It is characterized by contusions, damage to the vasculature,
axonal damage, and damage to the BBB. The continued insult exacerbates these physical
damages to the brain in the form of inflammation, ischemia, excitotoxicity, and the
interaction of free radicals, which is termed the secondary injury and continues to affect
the brain long after the primary injury is complete. A combined effect from the physically
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damaged tissue and the inflammatory response can lead to axonal degeneration,
demyelination, and apoptosis. The significant deficits express these issues in sensory,
motor, and cognitive impairments seen in TBI patients.
2.1.2

Experimental Model for Intracranial Traumatic Injury
Three types of forces are believed to cause TBI, including contact force, rotational

force, and intracranial forces.16–19 Contact force describes the force being applied to the
head or body.16,17 The rotational force is the force around a fixed axis.16 This force is
believed to be responsible for the damage to the deep white and grey matter, more
importantly, diffuse axonal injury.16 The intracranial forces result from the pressure wave
through the brain tissue created by the interaction between the brain tissue and skull.18,19
The intracranial forces cause damage deep into the brain, such as “blast trauma.”18 These
inertial forces cause traumatic axonal injury, defined as diffuse axonal injury (DAI) that
alters the function of the affected neurons.20
The midline fluid-percussion model is one model used for the experimental
evaluation of diffuse injury.15 This method can be achieved by delivering a fluid
percussion injury using a fluid percussion device.21,22 In this model, a craniotomy is made
in the organism’s skull (e.g., mice), and a controlled jet of water is injected through a
small hole in the skull and onto the dura mater of the brain, causing an intracranial
“wave” of forces across the brain.21–24
2.1.3

Biochemical Reaction During Secondary Injury
Adult mammalian neurons do not regenerate quickly, if at all. Cyclic adenosine

monophosphate (cAMP) is prominent during the growth phase of myelinated cells. It
tapers off as the neural cells transition from growth promotion to growth inhibition.25 The
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cAMP molecule then maintains a lower concentration in neural tissue (compared to the
growth phase) as it is important in synaptic transmission and mediates the action of
certain ion channels. This ubiquitous second messenger is also a crucial molecule in
several cell-signaling pathways of a developing neural cell.26 In the central nervous
system (CNS), increased cAMP levels stimulate regeneration by overcoming the myelin
growth inhibitors when arginase-I is up-regulated via a transcriptional activation through
the PKA pathway.11 The exchange protein activated by cyclic AMP 2 (EPAC2) also
promotes growth in neurons via activation of the b-RAF pathway.12 The primary
expression of EPAC2 is in the brain. It depends on cAMP, making the cAMP second

messenger a target for research (see Figure 2-2).13
Figure 2-2: An abbreviated overview of the cAMP pathway in the brain. An abbreviated
overview of cAMP pathway in the brain. Cyclic AMP is produced from ATP by adenyl
cyclase (AC). Phosphodiesterase (PDE) metabolizes cAMP in the cell to regulate its
intracellular concentration. The cAMP molecule is a ubiquitous second messenger
molecule critical for cell signaling, maintenance and regeneration by downstream
regulation of protein expression25. In neurons it is important in signaling, maintenance,
and brain development. This molecule is used in the protein kinase A (PKA) pathway and
the exchange protein directly activated by cAMP (Epac) pathway.25 Epac proteins readily
bind to cAMP and recruit the Ras superfamily (proteins).27,28 This pathway is believed to
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be associated with cell differentiation, proliferation, gene expression, apoptosis, and
phagocytosis.27,29,30
Cyclic AMP is produced from ATP by adenyl cyclase (AC). Phosphodiesterase
(PDE) metabolizes cAMP in the cell to regulate its intracellular concentration. The
cAMP molecule is a ubiquitous second messenger molecule critical for cell signaling,
maintenance, and regeneration by downstream regulation of protein expression.25 In
neurons, it is important in signaling, maintenance, and brain development. This molecule
is used in the protein kinase A (PKA) pathway. The exchange protein is directly activated
by the cAMP (Epac) pathway.25 Epac proteins readily bind to cAMP and recruit the Ras
superfamily (proteins).27,28 This pathway is believed to be associated with cell
differentiation, proliferation, gene expression, apoptosis, and phagocytosis.27,29,30
Cyclic AMP is produced by membrane anchor adenyl cyclase (AC). As a
ubiquitous second messenger, cAMP plays a major role in neuronal activity/regulation,
synaptic activity, plasticity, and gene expression.25,26,31 It is broken down by
phosphodiesterases (PDEs) which means its’ intracellular concentrations are governed by
generation by adenylate cyclase and degradation by the PDEs.6,8,25,32 PDEs are
upregulated after a TBI.6
2.1.4

Neurons
The brain is made up of multiple types of cells. The neurons, which consist of the

soma, axon, and dendrites, communicate via the movement of neurotransmitters that
cause a signal to pass along the cell. These cells rely on an electrochemical signal passed
down the axon through the axon terminal and downstream neurons' dendrites. During
TBI, the “inertial forces” acting on the brain causes axonal injury.15 If the damage is
significant enough, it can cause the neuron to fire excessively and cause dysfunction of
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this signaling system.15 This is the reason excitotoxicity is a symptom and related issue in
TBI. The damage to the cells causes the body to recruit and activate several non-neuronal
cells in the brain called glial cells. As an immune response, they are activated.
2.1.5

Glial cells
Glial cells, including astrocytes, microglia, and oligodendrocytes, carry out many

homeostatic functions in an uninjured brain. The microglia function is a macrophage
carrying out phagocytic roles in the CNS. In several instances, microglia have been seen
to phagocytose neurons that are damaged or dead.33 In homeostatic cases, microglia have
been seen to remove healthy neurons. It is theorized that they play a maintenance role in
securing new connections and removing old ones in the ever-changing dynamic brain.33
2.1.6

Astrocytes
Astrocytes or astroglia, the most numerous cell type in the CNS, gain their name

from their characteristic star morphology. These cells were originally identified as the
structural support of the neural network. Still, their function includes facilitating
neurotransmitter movement by facilitating myelin adhesion to the axon.34,35 In the
developing brain, astrocytes prune and clear un-needed axons and synapses; in developed
tissue, they enclose synapses, neuronal somata, or bundles of axonal internodes.36 Their
proximity has been shown to increase the lifetime and maturation of the dendritic process
forming more stable synapses. In these tissues, they also recycle (by reuptake)
neurotransmitters such as GLU and GABA.37–39 The main functions of astrocytes include
maintaining homeostasis, clearing debris, and protecting viable cells.40 They are
implicated in synaptic signaling, blood flow regulation, and communication with neurons
via Ca++ signaling.35,41
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There are two types of astrocytes: (1) fibrous astrocytes, typically found in the
white matter, and (2) protoplasmic astrocytes, typically found in the gray matter.42 As
shown in Figure 2-3, the morphology consists of a cell soma with numerous processes
extending from it. They are identified using antibodies to glial fibrillary acidic protein
(GFAP), a member of the intermediate filament (IF) superfamily member, which stains
the cell processes in immunohistochemistry (IHC) staining. GFAP is highly expressed in
fibrous astrocytes and produced by protoplasmic astrocytes, nonmyelinated Schwann
cells, and radial glial (RG) cells (non-differentiated neural cells).42,43 For more specific
identification, individual cell morphology is also considered.

Figure 2-3: Astrocyte stained using GFAP (A) non-reactive and (B) reactive. Astrocytes
or astroglia activation causes an upregulation of glial fibrillary acidic protein (GFAP, an
intermediate filament protein) during gliosis (activation of glial cells due to CNS
damage). GFAP can be identified using IHC staining techniques to visualize astroglia
cells. The astroglia illustrate a morphological change when activated; the size of their
soma (cell body) increases (white arrow) and the diameter or their processes increase
(black arrow) during activation. Scale bar = 10 µm.
Astrocytes or astroglia activation causes an upregulation of glial fibrillary acidic
protein (GFAP), an intermediate filament protein during gliosis, the activation of glial
cells due to CNS damage. GFAP can be identified using IHC staining techniques to
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visualize astroglia cells. As shown in Figure 2-3, the astroglia illustrates a morphological
change when activated; the size of their soma, cell body increases (white arrow), and the
diameter or their processes increase (black arrow) during activation.
CAMP is the second messenger that is found in astrocytes and functions via the
protein kinase A (PKA), the exchange factor directly activated by cAMP-1 (EPAC1), the
exchange factor directly activated by cAMP 2 (EPAC2), and the hyperpolarizationactivated cyclic nucleotide-gated (HCN) channel. The activation of the EPAC2 pathway
through pituitary adenylyl cyclase-activating polypeptide (PACAP) promoted astrocyte
differentiation.44 Phosphodiesterase (PDEs), such as PDE1 and PDE4, are the main
PDEs produced in astrocytes and are increased by the upregulation of cytokines.30,45
PDEs rapidly degrade cAMP, causing an inversely proportional relationship.
Upregulation of cAMP in astrocytes can also cause an increase in GLU
metabolism.46 Control of GLU metabolism may have implications in treatment by
negating excitotoxicity implications in neurotrauma; however, further research must be
performed. In TBI, the astrocyte’s initial activation is protective. Still, if persistent, it
results in an astroglia scar and prevents axonal regrowth after time.
2.2

TBI Therapeutics

Minocycline is a broad-spectrum tetracycline antibiotic developed in 1967 and
prescribed to treat various bacterial infections, including rickettsia, leptospirosis, certain
anaplasmosis, and Brucella spp.47 This FDA-approved antibiotic, at higher dosage levels,
has shown neuroprotective, anti-apoptotic, anti-inflammation, and anti-microbial
characteristics.47–51 In a moderate TBI model using a midline fluid percussion injury
(mFPI), a larger than normal therapeutic dose of minocycline (45mg/kg) was shown to
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decrease the development of terminal bulbs (see Figure 2-4) and axonal varicosities
when administered after a moderate TBI.13

Figure 2-4: Terminal bulb development with the treatment of minocycline.
Used under Creative Commons license. 52
Terminal bulbs are identified as swollen nodules along the axon that leads to the
termination and loss of the connections.53 In this study published in 2020, the two
treatment groups were delivered 45mg/kg of minocycline (Figure 2-4, Panel A) 45-mins
post-injury or (Figure 2-4, Panel B) 72-hours post-injury. Researchers used fluid
percussion (FP) to deliver a diffuse moderate TBI. In the histogram, there is a significant
difference between the development of terminal bulbs with minocycline treatment.
Delivering minocycline post moderate TBI reduces the percentage of terminal bulb
formation.
Varicosities are swellings along the axon that occur from breaks in the
cytoskeletal neurofilament.54–56 These varicosities can aid in developing terminal bulbs
by weakening the axon and causing it to retract upon itself, thereby losing the connection
to the sequel neuron.53 Terminal bulbs are caused by damage inflicted by a TBI and do
not require varicosities as a prerequisite for development.57
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Minocycline not only shows neuroprotective characteristics but has also been
shown to aid in axonal recovery.51,52 In one study to investigate the therapeutic effect of
minocycline post-moderate mFPI, a decrease in the development of varicosities due to
secondary injury was observed (see Figures 2-5 and 2-6). For these reasons, minocycline
is deemed a possible candidate for a neuroprotectant post TBI.

Figure 2-5: Images of axonal damage from a midline FP injury and repair comparing
(M-R & S-X) minocycline treated, (G-I) injured (untreated), and (A-F) Sham-injured
(untreated) mice. (Scale bar = 10 µm). Used under Creative Commons license. 52
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Varicosities develop due to damaged axons. In Figure 2-5, the third column of
images (M-R) was taken through a cranial window from a mouse treated with 45mg/Kg
of minocycline 45-minutes after a moderate TBI. The last column (S-X) shows images
taken from a mouse treated 72-hours post-injury. All three animals show structures
indicative of diffuse axonal injury (DAI), which include varicosities (>), terminal bulbs
(*), and disappearing axons (dashed arrow).

Figure 2-6: Development of new varicosities post moderate mFPI TBI in either treated
(minocycline) or non-treated mice. Used under Creative Commons license. 13,52
In Figure 2-6, the dark line indicates FN(t)=NtVt*100 where Nt=new varicosities
and Vt=number of varicosities. One hour after the injury, all varicosities were new,
indicated by the peak of the dark line (max=100%). The lighter, dashed line is described
by the formula FR(t)=Rt/Vt*100, where Rt is the number of recovering varicosities, and Vt
is the number of varicosities. All the varicosities are new at one hour, and none have
“recovered,” and so the value for FR(t) is 0%. The trend noted by this graph is that by 30
days after the treatment of minocycline, no new varicosities have developed, which
brings the FN(t) line to zero and the FR(t) line levels out. The trend is different from the
untreated TBI animals that continued to develop new varicosities as far out as 30 days.
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2.2.1

Phosphodiesterases and Rolipram
Phosphodiesterases (PDEs) are a group of catabolic enzymes that hydrolyze

cAMP.6 A prominent PDE in the brain is phosphodiesterase IV (PDE4) .6,7 Recent
research has focused on halting the effects of PDE4 to increase intracellular cAMP.7,9,30
Rm is a PDE inhibitor with antidepressant properties, was created in the 1990s as an
antidepressant.58 Clinical trials for the drug determined the therapeutic window was too
short, and the required therapeutic dosage caused extreme gastrointestinal distress, which
made the drug impractical as an antidepressant.58 More recent research has been aimed at
Rm as a PDE4 inhibitor to increase intracellular cAMP levels.6,7
Rm not only inhibits PDE but also influences other inflammatory proteins. Rm
upregulates the cytokine-specific binding protein, MAP kinase phosphatase-1 (MKP-1),
capable of inactivating the MAP kinase p38.59–61 MKP-1 promoter (DNA sequence)
includes two CREs which when bound to CREB, increases expression, which makes the
expression of MKP-1 directly proportional to the cAMP-PKA-CREB pathway.59 MKP-1
expression serves as a limiting factor for inflammatory responses.62 This downregulates
microsomal prostaglandin E synthase-1 (mPGES-1) associated with macrophage activity
and inflammation.59 This increase in MKP-1 also inhibits the expression of the
inflammatory cytokine TNF α.60,62,63
2.2.2

Poly(lactide-co-glycolide)-graft-polyethylenimine (PgP)
Poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) is a polymeric

amphiphilic micelle developed for high transfection efficiency when carrying a gene-load
and close association with cells important when carrying a drug load.12 PgP is developed
from poly (lactic-co-glycolic acid (PLGA) and branched polyethyleneimine (bPEI). The
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purified PgP particles can be doped with a variety of substances.4 The PgP nanoparticles
consist of a hydrophilic shell and a hydrophobic core.12 The hydrophilic shell allows for
increased binding of hydrophilic drugs while also gaining the ability for polyelectrolytes
to complex to the shell.12 For therapeutics, the hydrophilic shell allows the binding of
nucleic acids, which associates closer with the cell membrane and increases the
transfection efficiency.4,10,12 In spinal cord injury (SCI) models, PgP has been shown to
decrease the amount of damage from secondary injury by suppression of PDE4.4
PgP is synthesized by activating the carboxylic end group of PLGA and N, N’- dicyclohexyl carbodiimide (DCC; 72l mole), which results in a dicyclohexylurea byproduct
that can be removed by filtration. The remaining activated PLGA solution is slowly
added to bPEI. This reaction took place for 24-hours at room temperature with agitation.
PgP is then purified using a membrane filtration method and centrifuged to remove any
remaining substrates.11,12
The PgP nanoparticles can retain hydrophobic drugs, and nucleic acids are shown
in Figure 2-7.23 PgP are synthesized when activated PLGA is added to branched PEI and
purified. These PgP micelles can be doped with nucleic acids to increase association with
target cells and/or therapeutics.

Figure 2-7: Target-specific PgP micelle for nanotherapeutics. Used under Creative
Commons license.4
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Hydrophobic drugs can be added by a solvent evaporation method.4,12 Rm was
added in various concentrations to the PgP nanoparticles to determine the concentration
they would take up. As seen in Figure 2-7, a max concentration of 1.5 mg/mL of Rm
could be added to the solution for approximately 1.4 mg/mL of Rm to be loaded onto the
PgP. A higher concentration of added Rm caused precipitation due to supersaturation and
showed a drastic decrease in Rm loaded PgP. The most efficient concentration to load
PgP particles with was 1 mg/mL and resulted in an almost 1:1 added and loaded
(retention) efficiency. Rm, the hydrophobic drug, is slightly soluble in an aqueous
solution. The dashed line depicts this characteristic at 0.2 mg/mL in Figure 2-7.4
The nucleic acids are added by incubating PgP and nucleic sequence solution for
30 minutes at 37OC11. These nucleic acids can increase cell targeting and result in a
higher transfection efficiency when the nanoparticles (NPs) carry a gene load.10,64 PgP
carrying an adeno-associated vector of DNA with the code for β-galactosidase (β-gal) can
be used to visualize the PgP location in living, or previously living, tissue. The bacterial
gene β-galactosidase codes for a β-galactosidase enzyme. This enzyme is only present in
bacterial cells, and its presence in a mammal’s brain can only be attributed to the NPs
successfully transfecting the cells. These particles can be administered to test
administration routes and determine the presence of PgP in the target tissue. By using
immunohistochemical staining against β-gal, fluorescently labeled images can be
acquired. Cells that came in contact with the nanoparticles were transfected and fluoresce
for identification.10–12
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The hydrophobic drug Rm was tested for loadability and retention on the PgP
micelles.4 In Figure 2-8, Panel A, PgP was loaded with various concentrations of Rm to
determine the maximum concentration absorbed by the PgP.

Figure 2-8: PgP’s ability to load and retain a hydrophobic drug. Used under Creative
Commons license. 4
The loading method used was an ethanol evaporation method using 100 µL of
solution with various concentrations of Rm. The dashed line indicates the maximum
water solubility of the drug; any value over this line results from PgP uptake of the drug.
The loaded concentration (y-axis) increases with the amount of Rm added to the solution
(x-axis) until it peaks at 1.5 mg/mL. The drop-off in loadability is due to precipitation by
supersaturation. In Figure 2-8, Panel B, the graph displays the longevity of Rm remaining
on PgP. As illustrated, the solution is stable for up to 5-weeks, then it drastically drops as
the drug is disassociated.
2.3

Implications of Biosensor Development in TBI Research

The implications of TBI on the function of neurons can be further examined using
biosensors to monitor neurotransmitter activity in the brain. GLU and GABA are the
major excitatory and inhibitory neurotransmitters in the brain. The homeostatic balance

20
of the excitatory/inhibitory pathway is due to dynamically controlling the levels of GLU
and GABA under varying conditions.65 Disruption of this activity causes major
bioelectrical dysfunction.38,65,66 An excess of GLU leads to excitotoxicity which is known
to cause seizure activity.67,68 Conversely, a deficiency in GABA is also attributed to
seizures.38,66 neurotrauma results in widespread damage to neural cells, resulting in
excitotoxicity or immediate, delayed development. Understanding neurotransmitter
activity can aid in understanding the extent of such damage.
GLU/GABA levels are most commonly measured by microdialysis, which has a
very poor temporal resolution.66 With the development of certain biosensors, real-time
recording is possible, providing sub-second resolution.69–71 One such method of
GLU/GABA biosensor development involves using microelectrode arrays (MEAs) and
enzymatic coatings to yield an electrically active reaction product.69 GLU and GABA are
not electrically charged molecules. As such, they cannot be detected directly by
electrodes. However, using exogenous enzymes helps to break down these
neurochemicals producing H2O2, which is electrically charged. By coating electrodes
with enzymes that cause a reaction yielding H2O2, it is possible to record a current related
to neurotransmitter concentration. Biosensors that use this coating method include
microwires, ceramic shank style probes, and silicon-based shank style probes.69–71
Extensive discussion of these research findings are presented in Chapter 5.
2.3.1

Biosensor Implants with Enzymatic Coatings
The first probe discussed is a ceramic-based shank style probe with mounted

platinum (Pt) MEA and four-electrode recording sites. This biosensor probe has four
platinum MEA mounted directly on the shank. These electrodes can be coated with an
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enzyme coating to allow for neurotransmitter (GLU) recording. While testing in vitro, it
was found to measure GLU concentrations from 10-570 µM.69 The recording sites were
50 µm x 150 µm with 50 µm between each site and yielded a total recording area of 1.8
mm.69 An Ag/AgCl reference wire was used with a +0.7 V applied potential for H2O2
recording (Figure 2-9).

Figure 2-9: Ceramic-based platinum (Pt) microelectrode array (MEA) for real-time GLU
recording. The size bar is 300 µm.69
The electrode sites were coated in glutamate oxidase (GlOX), which catalyzes the
breakdown of GLU. This breakdown yields α-ketoglutarate, ammonia, and hydrogen
peroxide (Eq. 2-1).
Glu(E) + H2O + O2 →α–ketoglutarate + NH3 +H2O2(E)
H2O2 → O2 + 2H+ + 2e-

(Eq. 2-1)

Before implantation, the probe was calibrated to determine the sensitivity
calculation. This calculation was used to convert the current to concentration in data
analysis. Data were recorded using a multichannel FAST-16mkIII® potentiostat
manufactured by Quanteon, LLC, of Nicholasville, KY. The multichannel probe was
capable of measuring 10-570 µM GLU in vitro. No in vivo studies were published as only
in situ slice studies were performed. Eq. 2-1 explains the reaction at the electrode site.
GLU is oxidized by glutamate oxidase (GlOX), which yields α-ketoglutarate, ammonia,
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and hydrogen peroxide. The second line of Eq. 2-1 shows the hydrogen peroxide is then
oxidized at the Pt surface and results in the release of two electrons, causing a recordable
current.69
The next generation of enzyme-coated probes included Pt electrodes coated for
GABA and GLU recording. These probes utilized the same enzymatic reaction used for
GLU recordings along with a further analysis of GABA. Equation 2-2 describes the
GABA and GLU reaction in a three-step process.
Glu(E) + H2O + O2 → α–ketoglutarate + NH3 +H2O2(E)
GABA + α–ketoglutarate → SSA + Glu(GABA)
Glu(GABA)+ H2O + O2 → α–ketoglutarate + NH3 +H2O2(GABA)

(Step 1)
(Step 2)
(Step 3)
(Eq. 2-2)

Abbreviations for Eq. 2-2 are, as follows:
GLU(E) = environmental GLU,
H2O2(E) = H2O2 from GLU(E),
SSA= succinic semialdehyde,
GLUGABA = GLU from GABA oxidation,
H2O2(GABA)=H2O2 from GABA two-step reaction.
Process Step 1 is the same as Eq 2-1 and derives an electrical current from the
presence of GLU. In Step 2, GABA is measured using GABAse and α-ketoglutarate. Due
to the unsustainability of α-ketoglutarate in vivo, it is produced at the site. The GABA
probe is coated with glutamate oxidase and GABase. In Step 1, we see α-ketoglutarate is
a product of reaction; however, in Step 3, α-ketoglutarate is produced in a high enough
concentration to interact with GABA and in the presence of GABase produce H2O2. 11
These recordings were made in the hippocampus of a rat brain slice. The
electrodes were sized at 100 µm × 50 µm (Figure 2-10). The electrodes were placed on a
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shank and grouped in pairs spaced 1 mm apart. Each set was spaced 50 µm from the other
site. The Pt sites were 150× 50 µm. The major improvement of this probe is its’ ability to
record GABA and GLU. The enzymatic coating is described by Eq 2-2.71

Figure 2-10: GABA/GLU reactively coated Pt MEAs. (A) the full scale ceramic shank
(B) inset of the blue oval in image (A) Used under Creative Commons license.71
The final sensor is depicted in Figure 2-11 to illustrate the broad use of enzyme
coated biosensors. This sensor used the same enzymatic coating as described in Eq. 2-2.
The microwire array comprised three wires for GABA, GLU, and sentinel and was
gathered and secured in heat shrink tubing. (Figure 2-11). These wires were implanted in
cannulated rats and recorded using the FAST analysis system. The microwire array was
designed to be removable. Over time endogenous enzyme activity can strip the
biosensors of their coating. A replaceable microwire sensor was developed to combat that
issue.72
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Figure 2-11: Novel microwire array. Scale bar = 100 µm. Used under Creative
Commons license. 72

CHAPTER 3
NANOPARTICLE DELIVERY OF THERAPEUTICS TO TREAT
TRAUMATIC BRAIN INJURY
3.1

Traumatic Brain Injury

TBI is caused by forces acting on the neuronal tissue that causes axonal shearing,
contusions, damage to the vasculature, damage to the blood-brain barrier, and other
previously described issues. These mechanical damages are the primary injury and cause
a biochemical imbalance in the neuronal tissue, known as the secondary injury. This shift
causes the release of free radicals, excitotoxicity, ischemia, and inflammation.1,22,73
Symptoms of the secondary injury can arise from hours to years after the injury as the
cascading effect of the molecular imbalance causes more damage.1,74 No medication for
specifically treating secondary damage due to TBI is currently marketed. To limit
secondary damage, doctors may administer steroids, diuretics, anti-seizure medication,
and NSAIDs to treat the issues associated with TBI symptomatically.73,75,76 One of the
largest obstacles in treating these injuries is getting therapeutics to the target tissue. The
fastest and most effective means to deliver drugs to the brain is direct injection. Due to
the relative size, multiple injections would likely be required, causing more damage to an
already damaged organ and in a medical environment would be considered ethically
questionable.
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3.1.1

Possible Routes for Therapeutics
Recent neuroscience research has investigated Rolipram (RM) as a possible CNS

treatment for neurotrauma.4,6,9,30,74,77 Rm is a phosphodiesterase (PDE) type IV inhibitor
that reduces the breakdown of cAMP.6 Cyclic AMP, synthesized from membrane-bound
adenyl cyclase, is a ubiquitous second messenger molecule that plays an important role in
neuronal activity/regulation, synaptic activity, plasticity, and gene expression
regulation.78 This molecule acts as a precursor for protein kinase A (PKA) pathway
activation and affects its gene expression.25 The cAMP molecule also plays an important
role in the regulation of action potential in neurons.25,26,74 The cAMP molecules are
catalyzed by PDEs, and in a homeostatic brain, maintain balanced levels of cAMP. They,
specifically PDE4, are commonly found in immune/inflammatory cells and are
upregulated during inflammatory conditions. Inhibiting PDE has been shown to have
anti-inflammatory/neuroprotective characteristics. The use of Rm to stop the break-down
of cAMP can upregulate protein production and, theoretically, produce a sequalae
pathway for restructuring post-injury.6 This drug is the blood-brain barrier (BBB)
permeable, and in several studies, it functions as a neuroprotectant to reduce macrophage
activity, reduce inflammation, reduce axonal damage from secondary injury, and support
axonal regeneration.4,5,8,9,77 The disadvantages of using Rm as a treatment are problematic
side effects, including extreme nausea, vomiting, and headache, and deter using an oral
therapeutic dose. 4
3.1.2

Poly(lactide-co-glycolide)-graft-polyethylenimine (PgP)
Poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) is a polymeric micelle

developed to target neural cells and high transfection efficiency when carrying a
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gene-load and close association when carrying a drug load.12 These NPs were developed
by Dr. Jeoung Soo Lee at Clemson University as a targeted drug delivery to the spinal
cord of spinal cord injured (SCI) rats. PgP was created by activating the carboxyl ends of
poly-lactide-co-glycolide (PLGA), removing the urea byproduct, and adding the PLGA
solution to branched polyethyleneimine (bPEI).4,12 The resultant cationic amphiphilic
copolymer was then purified and could be doped with a variety of substances.4 The final
size of the PgP particles are 123.5 ± 3.5 nm.12 The use of PgP showed a higher
transfection of pDNA and reduced cytotoxicity when compared with bPEI
nanoparticles.11 PLGA has also been implicated as a nanoparticle drug delivery system.
PLGA has FDA approval but does not result in transfection as high as bPEI, or PgP.12,79
PgP has also been shown to carry and transfect nucleic acids (siRNA and DNA) neural
cells with increased efficiency.10
3.1.3

Characteristics of PgP
The PgP nanoparticles consist of a hydrophilic shell and a hydrophobic core.12

The hydrophilic shell allows for increased binding of hydrophilic drugs while also
gaining the ability for polyelectrolytes to complex the shell region.12 The polyplex also
shows an affinity for retention of siRNA and pDNA.10 In hydrophilic drugs, PgP
complexed the rolipram (Rm-PgP) was stable for up to five weeks.4 The hydrophilic shell
allows the binding of nucleic acids, which associate closely with the cell membrane and
increase the transfection efficiency.4,10,12 The size range of PgP-Rm is 121.8 ±1.9 nm.4
Furthermore, Rm’s PgP delivery method was used to successfully treat SCI and repair
damage from this injury in rat models.4
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3.1.4

PgP as a Vector for Drug Delivery in the Brain
The characteristics of PgP as a drug delivery vector have previously been

investigated. PgP was conjugated to DiR, a near-infrared fluorescent dye, and injected
directly into mouse neural tissue with a cranial window.13 The point of injection was then
capable of being imaged for several days post-injection. The PgP particles were
distributed through the brain parenchyma in the region near the injection site over 24hours. They also persisted for three days, which showed contact longevity and sufficient
distribution.13 Fluorescein isothiocyanate conjugated to dextrin Ex/Em (FITC-dextrin )
490nm/530nm was used as a fiduciary marker to label the vasculature and was visible up
to 3-days post-injection. The conjugation of dextran increases the size of the molecules,
so they do not readily escape the vasculature. DiR (DiIC18 (7) (1,1’-Dioctadecyl3,3,3’,3’-Tetramethylindotricarbocyanine Iodide) was attached to the PgP nanoparticles.
These molecules excite at 750 nm and emit at 779 nm (see Figure 3-1).

Figure 3-1: PgP-DiR cortical injection with FITC-Dextran vascular counterstain. Images
were pseudo-colored in post edits using ImageJ; the image was taken by Dr. Chelsea
Pernici (unpublished).
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After injection of FITC-Dextran (490 nm/530 nm) and PgP-DiR (750 nm/ 779
nm) direct injection, MPM in vivo images were acquired through a cranial window at
1-hour, 3-hour, 6-hour, 24-hour, 3-day, and 6-day post-injection. FITC-Dextran, which
was used as a fiduciary marker, was visible up to 3-days post-injection. PgP-DiR was
concentrated in a localized area (arrow) at 1-hour. At 3-hours post-injection, the PgP-DiR
spread along vascular pathways (arrowheads) and occupied a larger area than the 1-hr
time point. At later time points, the PgP-DiR spread more uniformly through the
parenchyma. It was still visible at the 3-day time point. By 6-days, the PgP-DiR, as well
as FITC-Dextran, were no longer visible in the tissues.
In unpublished work by Dr. Chelsea Dressel Pernici, the NPs showed an ability to
transfect various cells after an intraventricular injection. In Figure 3-2, Panel A, cells
lining the lateral ventricles and in periventricular areas (arrows) were transfected. In
Figure 3-2, Panel B, another tissue region near the ventricle has been transfected.

Figure 3-2. Transfection of cells by PgP-DiR/pβ-gal vector after intraventricular
injection. Transfected cells were labeled with anti-β-gal (green); cell nuclei were stained
with DAPI (blue). Images were taken using MPM with a 10x lens—image taken by Dr.
Chelsea Pernici (unpublished).
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PgP-DiR/pβ-gal complexes appeared to move freely through the cerebral spinal
fluid of the lateral ventricles. Although the injection was in one hemisphere, cells around
ventricles in both hemispheres were transfected. The transfection was expected because
the ventricles in the two hemispheres are connected. Moreover, cells in the overlying
cerebral cortex were transfected, suggesting that the NP complexes were not repelled by
beating cilia of ependymal cells lining the ventricles and that they traversed this barrier
into the parenchyma. Thus, intraventricular injection into the lateral ventricle could be an
effective route of administration for emergency application of Rm-PgP (see Figure 3-3).
However, a less invasive route of administration should be explored.

Figure 3-3. High-resolution images of cells transfected after PgP-DiR/pβ-gal injection.
Nuclei were stained with DAPI (blue); transfected cells were labeled with anti-β-gal
(green). Images were acquired using MPM with a 10x lens—image taken by Dr. Chelsea
Pernici (unpublished).
Figure 3-3, Panel A shows the periventricular area. Cells near the ventricle stained
positive for β-gal, the gene for which was carried on PgP and transfected the cells. Figure
3-3, Panel B shows the cerebral cortex. Cells in the cortex were also transfected after the
intraventricular injection showing the polyplex nanoparticles could move throughout the
neural tissue Figure 3-3, Panel C is the control region. This region in the brain had no
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positively transfected cells. The background (green punctate staining) is similar to
controls for non-specific binding of the secondary antibody (not shown).
3.1.5

Hypothesis
This project aims to prove that the PgP polyplex nanoparticles are capable of

passing through the BBB and coming in contact with neural tissue post-injury after being
administered intravenously or, as an alternative, intranasally to provide a less invasive
route of administration. The null hypothesis states that the NPs cannot be observed
transitioning the BBB and cannot affect the cAMP level when PgP-Rm is administered.
3.2
3.2.1

Methods

Animal Care and Use
All animal testing used healthy adult mice weighing 17 - 30 g, C57BL/6NHsd,

from Jackson labs or bred in our facility from this line. Before experimentation, animals
were evaluated for fitness and overall health based on body condition scores (BCS),
reactivity to researcher interaction, and general activity in their environment.80–82 They
were housed under a 12-hour light/dark cycle. Animals were allowed food and water ad
libitum, and all experiments, handling, and euthanasia were performed according to a
protocol approved by the Louisiana Tech University Institutional Animal Care and Use
Committee (IACUC).
3.2.2

Anesthesia
Mice were anesthetized using 500 mL/min isoflurane plus room air administered

by a SomnoSuite ® low-flow electronic vaporizer manufactured by Kent Scientific
Corporation. The product was administered at an increasing rate from 0.4%-2% over 4-5
minutes to decrease the chance of respiratory distress.83 The surgical plane of anesthesia
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was determined by a lack of response to a noxious toe pinch or light pressure on the
cornea. Once the plane was reached, the mouse was administered an intraperitoneal (IP)
injection of a premixed solution of ketamine (10mg/Kg) and xylazine (1mg/Kg) (K/X).
While the mouse was in a supine position, the IP injection was made at a 40º angle in the
lower left quadrant of the abdominal cavity. Body temperature was maintained using an
electronically controlled heating pad from Kent Scientific Corporation. Ophthalmic
ointment was applied to the eyes to avoid drying while the subject was under sedation.
The animal’s breathing, pain response to noxious stimuli, and body temperature are
evaluated every 15-minutes.
3.2.3

Injury Hub Implant
Mice were placed under anesthesia and sedated using the approved protocol. After

the plane of anesthesia was achieved, the animals were secured in a stereotaxic mouse
frame for stability. A midline incision was made exposing the lambda and bregma, and
the skull was cleared of all connective tissue. Approximately 1mm thick weed-whacker
twine was used as an anchor and was attached using cyanoacrylic on the midline between
the lambda and bregma for the craniectomy.21,22 This anchor guided the trephine as a 2.5
mm craniotomy was created. Trephining stopped once the bone flap separated enough to
be removed with fine forceps and exposed the dura (Figure 3-4). The dura remained
intact for all mice used in the study. Special care was taken during this step to place the
hub in the correct location and reduce surgical implications in the project.84
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Figure 3-4: Midline craniotomy. A midline craniotomy was performed using a hand-held
trephine to remove the 2.5 mm diameter section of the skull between lambda and bregma.
Special care was taken not to disrupt the dura, the site of injury hub implantation.
The site was framed by an injury hub that was a cut female Luer-Lock plastic
needle hub from a 20-gauge needle. The hub was cut just before the tapering of the LuerLock needle using a Spectrum tube-cutter to maintain uniform hub production. The hub
was secured using cyanoacrylic (KrazyGlue ®) and then anchored with PMMA, Lang
dental acrylic, bone cement. The Luer-Lock hub acted as the connection point between
the animal and the fluid percussion (FP) system. When not in use for injury, 0.9% sterile
saline solution was placed in the hub to retain moisture in the dura mater. A parafilm was
placed over the hub to retain the saline solution and to decrease the chance of foreign
material entering the injury site.
3.2.4

Fluid Percussion Injury
A midline fluid percussion injury (FPI) was performed using a fluid percussion

(FP) device from Custom Design & Fabrication, Virginia Commonwealth University,
Richmond, VA, and resulted in a diffuse brain injury (see Figure 3-5).
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Figure 3-5: Fluid percussion injury devise. The FPI device was comprised of an (A)
pendulum, (B) hammer, (C) water-filled piston, (D) pressure sensor, and (E) tube for
connection to the injury hub on the mouse. The sedated mouse was attached to the female
Luer-Lock connector (E). Once the animals began to stir, the hammer (B) was dropped
on the piston (C), pushing a jet of water through the tubbing. The parameters of injury
were measured by a mounted sensor (D).
The FP device delivered a controlled jet of water into the injury hub for a uniform
injury. Injuries were performed 6-8 hours after the injection of surgical anesthesia (K/X)
to reduce complications from the interactions between the K/X and isoflurane. TBI hub
installation surgery and injuries were performed within 12 hours to reduce the chance of
infection or foreign objects in the craniotomy. Before attempting injury, the air bubbles
were flushed from the fluid-filled piston and tubing. Any residual air bubbles can vary
the accumulation of pressure in the piston, thereby changing the resultant injury.21,85
Mice were anesthetized using 500 mL/min isoflurane plus room air administered
by a SomnoSuite ® low-flow electronic vaporizer at an increasing rate from 0.4%-2%
over 4-5 minutes to decrease respiratory distress (see Figure 3.6).
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Figure 3-6: Attaching injury hub to the device. (A) The injury hub (yellow plastic
connector) was opened by removing the Parafilm cover, which was placed post-surgery.
The hub was re-filled with sterile saline. (B) The Luer Lock hub was then connected to
the tube for animal connection (feature E in Figure 3.5).
Once the plane of anesthesia was achieved, the mouse was removed from the
induction chamber, and the protective parafilm was removed to expose the dura, as
shown in Figure 3.6, Panel A.85 The 0.9% saline in the hub was inspected for debris and
refilled. Figure 3-6, Panel B shows the injury hub connected to the female Luer-Lock
connection of the FP device. The mouse was allowed to recover from the anesthesia
slightly. As soon as the mouse began to stir, the hammer was dropped on the FP device
from an angle of 17.5.º The hammer would hit the piston, releasing a controlled jet of
water through the hub to cause a build-up of intracranial pressure that results in a diffuse
TBI.85 The injury lasts approximately 20 ms and ranges from 304-340 mV max, equating
to a pressure of 2.8-3.5 atm.
The severity of the injury was based on the amount of time for the animal to
exhibit a righting response.22 The righting response is the amount of time it took the
animal to regain enough consciousness to rotate themselves from a supine position to all
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four feet. A mild TBI was characterized by a righting response time of less than six
minutes, and a moderate TBI was between 6-10 minutes.22,23 For a severe injury, the
righting time was defined as greater than 10 minutes. A higher mortality rate
accompanied severe injuries.22 A series of vestibulomotor tests were conducted to refine
the injury severity classification. These test results were combined to produce what is
generally called the modified neurological severity score (mNSS).86,87 Only moderately
injured mice were used for this project.
Mice were either injured or had a sham injury. For the sham injuries, animals
were implanted with the surgical hub and connected to the FP device, but the hammer
was never dropped, so no TBI occurred. Besides the injury, all handling/procedures were
performed as outlined to ensure continuity. These animals created a baseline to rule out
any surgical/handling implications that could influence results.
3.2.5

Post-injury Cap over Craniotomy
After the injury, the mouse was placed under isoflurane to analyze post-injury

damage and apply a cap over the craniotomy to protect from further injury. The hub and
dental acrylic were removed, exposing the skull and open craniotomy. The brain was
observed for hematoma or herniation, a breach of the dura. During the surgical implant of
the hub, the dura could be compromised, allowing for extensive herniation post-injury.85
The injury hub was also observed for any type of occlusion. An occlusion could result in
an improper injury by changing the size of the craniotomy. Animals with herniation or
occlusion of the injury hub were removed from the study as their injuries did not match
the experimental parameters. Herniation size and hematoma size/presence were noted on
the injury log. A protective layer of 1-2% agarose gel was cut and placed on the
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craniotomy opening. The gel and exposed skull were then sealed using bone cement
(PMMA) to protect the brain from physical damage, bacterial infection, or debris. Mice
were then administered a nanoparticle treatment before being returned to a clean cage.
Food and water were provided ad libidum for three days. Following the three-day
incubation to allow for adequate dispersion of PgP and the expression of the selective
marker, the brains were harvested.
3.2.6

Administration Route of Nanoparticle Treatments
Two routes of administration of nanoparticles were tested and are described

within this section. All particles were made, characterized, and shipped from Dr. Jeoung
Soo Lee’s lab in Clemson University, Department of Bioengineering. A PgP/pβ-gal
polyplex solution was prepared by complexing an adeno-associated plasmid (with the βgalactosidase gene) (2.74µg/µL) to PgP (10mg/mL) in sterile water. This solution was
used to verify the delivery of NPs in neural tissue and its distribution across the various
tissues. β-galactosidase, or β-gal, produces an enzyme that catalyzes lactose in bacterial
cells. The presence of β-gal in a murine brain can only be attributed to the transfection of
the β-gal gene in the cell. The cellular machinery produces the protein from the DNA
sequence delivered by the PgP nanoparticles. PgP (10mg/mL) with no viral vector was
also prepared in sterile water as a control. If necessary, the solutions were diluted to
1mg/mL and delivered post-injury using the intranasal (IN) and intravenous (IV)
administration routes. Treatments were delivered 30-45 minutes after the righting
response post-injury.

38
3.2.7

Intranasal Administration
The intranasal dosage was 24 µL of NPs (1 mg/µL). The solution was divided, so

the animal received an equal volume of treatment in the right and left nasal cavity. Doses
of NPs for both the right and left were divided into 2-drops containing 6 µL then
delivered to each nasal cavity. While under isoflurane anesthesia, the mouse was
dispensed 6 µL using a micropipette to the right nostril opening. As soon as the first drop
was inhaled, 6 µL was administered to the left nostril. The mouse was allowed to rest for
at least one minute after the initial dosage before the procedure was repeated. The process
continued until the full dose was administered.88
3.2.8

Intravenous Administration
An intravenous dispensation (IV) was used in a tail vein as a second drug delivery

method. The mouse remained sedated using isoflurane and placed on a warming pad to
increase the vein’s proximity to the skin. The vein was restricted anterior to the injection
site, the needle was inserted, and the restriction was released. The proper placement was
ensured when the solution was capable of being injected easily. Mice were administered
100 µL of treatment via IV administration.
3.2.9

Tissue Harvest and Preparation for IHC

3.2.9.1

Cardiac perfusion
Animals given the pβGal conjugated nanoparticles were harvested after three

days. The mice were sedated using isoflurane and then administered K/X. Once the plane
of anesthesia was achieved, the mouse was stabilized in a supine position. Two incisions
were made along the base of the ventral ribcage and continued laterally. A thoracic
midline incision was performed beginning at the xiphoid process and extending through
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the clavicle. The ribcage was restrained using two hemostats to reveal the thoracic cavity.
The exposed aortic arch was slightly snipped, and a 27G needle with ice-cold phosphatebuffered saline (PBS) was inserted into the left ventricle using a fixed flow infusion
machine. Approximately 15-20 mL of ice-cold PBS were run through the circulatory
system before 15-20 mL of 4% formalin solution was then circulated. Special care was
taken so no bubbles/air entered the system as this could collapse the vasculature (see
Figure 3-7).

Figure 3-7: Dissection lines. Two lateral lines (A.) were made along the base of the rib
cage to perform cardiac perfusion. A midline (B.) was then made through the xiphoid
process and rib cage to expose the thoracic cavity.
3.2.9.2

Harvest of fixed tissue
After cardiac perfusion, the mouse was decapitated. The cap covering the

craniotomy was removed, and the epidermis was partially removed from the skull. Any
residual vertebrae were removed using scissors, and the skull was removed from the
animal using hemostats. Once visible, the brain was coaxed out using a spatula and rested
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in formalin for 15 hours at 4ºC. The brain was then rinsed in PBS before being allowed to
saturate in a gently rocking 30% PBS sucrose solution held at 4ºC. The tissue was then
prepared for long-term storage by leaving at 4ºC or submerging it in liquid nitrogen to
snap freeze.
3.2.9.3

Slicing
Slicing of the brain was performed using a Leica microtome and a freezing stage.

Samples were removed from the freezer and left on the ice to thaw slightly. The brain
stem and olfactory bulbs were removed, and the brain was placed on its caudal end to be
mounted on the freezing stage using the TissueTrek OCT compound. Coronal sections 30
µm thick were made and placed in a 24-well plating tray in the 30% sucrose (PBS)
solution. Slices were stored at -20ºC until they were stained.
3.2.10

Verification of Nanoparticle Delivery Treatment Groups

3.2.10.1

IHC staining for β-galactosidase

After slicing, sections were left in a humidifying chamber for 5-minutes at room
temperature. The tissue was then fixed with ice-cold methanol for 5-minutes before being
rinsed with PBS. Cells were then permeabilized with PBS containing 0.1% Triton x-100
(PBST), then washed with PBS. The slices were incubated at room temperature for one
hour with 10% bovine serum albumin termed BSA in PBS. They were then incubated
with the primary antibody overnight at 4ºC. The primary antibody was derived from
chicken for β-gal, diluted 1:200 (Abcam). The next day the slices were washed with PBS.
The secondary antibody was added and incubated for 2-hours at room temperature. The
secondary antibody used was donkey anti-chicken Alexa Fluorophore 488 (AF 488),
diluted 1:500 (Abcam). Residual secondary antibody was washed off using PBS. Slices
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were moved to slides and mounted using FluoroShield™ with DAPI, sigma. Controls
were only stained with the secondary antibody, and a Nikon camera was used to take
images on an epifluorescent microscope. AF488 and DAPI were taken separately and
converged using image analysis software.
3.2.11

Image Analysis
Images were taken with a Nikon camera on an epifluorescence microscope. Two

images using the GFP then the DAPI filters were taken. Images were processed using
ImageJ v1.53e. The image was converted to 8-bit (black/white), and the background was
subtracted. The brightness and contrast were then adjusted to similar values between each
image. The DAPI and β-gal signals were assigned pseudo color for distinction. DAPI was
assigned red, and the β-gal signal was assigned green. The two channels were then
converged using the overlay function.
3.3
3.3.1

Results

Nanoparticle Targeted Delivery System
The intranasal (IN) and intravenous (IV) administration routes were tested. The

first study investigated a qualitative analysis of the ability of the nanocomposite to
encounter neural tissue. Four mice were originally tested for either IN or IV
administration using PgP/β-gal and visualization using IHC staining (n=2). These images
were taken on the multiphoton microscope and had low signal, resulting in low-resolution
images.
The test groups were repeated using four mice with PgP/β-gal (n=2). The PgP/βgal treatment was compared with PgP only treatment to negate any possible
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autofluorescence from the nanoparticles. Images were taken using a multiphoton
microscope (MPM) and then compared (see Figure 3-8).
IN
Administration

IV
Administration

PgP/β-gal

PgP

Figure 3-8: Epifluorescent imaging of AF488 and DAPI overlaid using ImageJ. Postinjury, mice were administered PgP/ β-gal. IHC staining for β-gal using AF488 marker
showed distinctive neurons (shown in green) in both the IN and IV administration routes.
The cells were counter-stained with DAPI (shown in red) to show nuclei. The β-gal
signal was assigned green, and the DAPI signal was assigned red in edits (ImageJ).
An identification showed an AF488 signal in the shape of a neuron surrounded by
the DAPI stain on the nuclear material. All mice involved in the qualitative analysis were
injured with a moderate TBI. As seen in Figures 3-7 and 3-8, both administration routes
of PgP/β-gal had positive cells. The PgP treated animals shown in the bottom row
showed no signal in the AF488 channel.
These tests were expanded upon by visualizing various locations in the brain. In
both IV and IN administrations, the NP dispersed throughout the striatum with a slightly
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higher intensity of signal as you move toward the midline. There was also little to no
signal in the cortex. No further analysis was done on the intensity (see Figure 3-8).
Brains were sliced in coronal sections showing a relatively similar lateral signal
from AF488. Also visible in Figure 3-8 is the deposition of the nanoparticles visible in
the brain's septo-striatal and caudal diencephalon regions. This type of distribution was
seen in both the IN and IV administered routes.

Figure 3-9: IHC staining of β-gal in coronal 60 µm section. Slices taken from the caudal
diencephalon region (A and C) and slices taken from the septo-striatal regions (B and D)
all had a positive signal from staining when compared between IN and IV administration.
The β-gal signal was assigned green, and the DAPI signal was assigned red in edits
(ImageJ). The first column shows the AF488 signal; the second column shows the DAPI
signal; the third column overlays the AF488/DAPI images. The last column is an inset of
the third column image (the area zoomed in is shown in the blue square in the third
column. The cortex has minimal stained cells, as can been seen in (A). Images were taken
on an Olympus epifluorescent microscope. Images were adjusted using ImageJ to optimal
viewing and assigned a pseudo color using red DAPI and Green AF488.
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3.4

Discussion

Preliminary data showed β-gal in mouse neural cells post-injury and
administration of IN and IV PgP/DiR/β-gal polyplexes. The expression of β-gal, a
bacterial protein not naturally present in mouse neural tissue, could only be linked with
the presence of NPs carrying a vector with the β-gal gene that has come in close contact
and transfected neural cells. Previous work has shown the ability of the NPs to move
across various cell types, but the invasive direct injection manner of administration
caused additional mechanical damage to the tissue.13 The less invasive IN and IV routes
of administration were tested after injury, resulting in the NPs successfully passing the
BBB, thereby mitigating invasive approaches such as direct injection.
Coronal sections in both the caudal diencephalon region and the septo-striatal
regions were visualized. Both regions had transfected cells from the IN or the IV
approach and demonstrated that this approach successfully delivered widely-dispersed
NPs to the brain. These findings validate our hypothesis for using a less-invasive yet
efficient route of administration. The diffuse injury models used in this study indicate an
injury caused by a car wreck with a concussion but without a penetrating injury.22
Showing that PgP can be used as a delivery vector capable of being visualized throughout
the neural tissue increases its practicality as a possible drug delivery system for TBI
treatment.

CHAPTER 4
COMBINATION DRUG THERAPY FOR TBI TREATMENT
4.1

Introduction

No direct therapeutic for TBI is on the market today. As described in Chapter 2,
current treatment methods include addressing the symptoms of the TBI. Chapter 3
evaluated the validity of PgP as a delivery vector for therapeutics into the brain postinjury. The therapeutic Rm has previously been observed to possess neuroprotective
characteristics and reduce secondary injury in the rat SCI model.5,30,77,89 This fast-acting
drug is proposed to be combined with minocycline, a broad-spectrum tetracycline
antibiotic. In previous research, minocycline was observed to reduce the number of
developing varicosities post-injury.13 The therapeutic effect was not observed until 7days post-injury. The use of targeted Rm delivery is expected to reduce the secondary
damage immediately after injury and continue this effect until the efficacy of minocycline
is observed.
As mentioned in Chapter 2, minocycline, although capable of reducing the
number of new varicosities formed after TBI, take 14-30 days to visualize a therapeutic
effect.13 This alone may not be a valid treatment option for TBI, but in conjunction with a
faster acting therapy may be potentially advantageous. Utilizing the PgP nanoparticles to
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deliver a targeted, low dose of the drug directly to affected tissues increases the
possibility of utilization and decreases the chance of adverse side effects.
The therapeutic effect of the PgP-Rm and minocycline can be evaluated with
sensory, motor, and cognitive behavioral tests and histological analysis of the brain
tissue. The behavioral tests include rotarod for balance and motor coordination,
neurological severity tests to assess neurological impairments due to injury, open field for
locomotor activities and anxiety testing, novel object memory recognition, and elevated
plus maze for anxiety. For the histological evaluation, astrocytes are stained using GFAP
and measured for reactivity. Astrocytes or astroglia are activated and upregulate GFAP
during astrogliosis. For a more extensive description of the process, see Chapter 2.
4.1.1

Hypothesis
We expect to observe greater downregulation of astroglia activation at seven days

after a moderate TBI when PgP-Rm and minocycline are administered post-injury versus
either drug administered alone. The null hypothesis is that there is no difference between
these treatment groups.
4.2

Materials and Methods

All injuries, treatment, behavioral tests, and harvest are performed between 5 PM
and 10 PM to maintain consistency. Animal handling and injury infliction were reviewed
in detail in Chapter 3. Mice were implanted with an injury hub in the morning and
injured more than 6-hours after a K/X injection to ensure there was no interaction
between the ketamine and the isoflurane.
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4.2.1

Treatments
The combination drug therapy included 24 µL intranasal administered PgP-Rm

(1mg/mL) delivered 30 minutes to an hour after injury, and the second was an
intraperitoneal (IP) minocycline (45 mg/kg) injection (Tocris Bioscience). The IP
injection was delivered 45-minutes to an hour after injury for initial dosage and then for
five consecutive days after injury (within the same treatment time window). For the
vehicle control groups, mice were given 0.9% saline (Teknova, Hollister, CA) IP
injection in place of minocycline and water or PgP (with no added drug) IN in place of
the PgP-Rm. A PgP control was included due to the very moderate effect that was
observed when treating SCI4. These treatment groups are listed in Table 4.1.
Table 4-1:

Treatment Groups for Combination Drug Therapy

Sham injury + Vehicle (IP) + Vehicle (IN)
TBI-injured + Vehicle (IP) + Vehicle (IN)
TBI-injured + Vehicle (IP) + PgP (IN)
TBI-injured + Vehicle (IP) + PgP-Rm (IN)
TBI-injured + minocycline (IP) + PgP-Rm (IN)

Mice were randomly assigned to each treatment group, and the animals were
harvested after 7-days post-injury. There were three animals in each of the five treatment
groups.
The IN-administration protocol is described in Chapter 3. Due to the observed
transfection of cells in contact with PgP, the IN administration was deemed a sufficient
administration route. IP injections were performed on mice anesthetized with isoflurane.
While in a supine position with the head angled down, the mice were injected at
approximately a 40º angle in the lower left quadrant of the abdominal cavity using a half-
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inch long 27-gauge needle. Only the needle tip entered the intraperitoneal cavity to avoid
damage or injection into the intestines or other vital organs.
4.2.2

Behavioral Test
The following tests are used to determine sensory, motor, and cognitive

impairments post-injury.
4.2.2.1

Rotarod
Rotarod testing consisted of acclimation and testing the impairments in motor

skills associated with TBI impaired animals.90 The mouse was first placed on the
stationary rod to balance for 30-seconds. If the mouse fell, it was immediately replaced,
and the timer was started again. The next step was for the animal to walk on the bar at a
constant rotation of 5 RPM for 15-seconds. If the mouse fell off the bar, it was replaced,
and the timer was re-started. The acceleration was set to 0.2 RPM/second for the final
step, with a final speed of 30 RPM/second. The speed and time at which the mouse fell
off were recorded.
This process was repeated and recorded three times per day. The first two trials
were run sequentially, and the mouse was returned to its box after the second trial. After a
10-minute rest, the mouse completed the third and final trial for the day. After each day
of recording, the best two times were averaged together; these are the values reported.
Rotarod tests were performed on days -3, -2, -1, 2, 5, and 7. Days -3, -2, and -1 provided
an acclimation period, and the baseline was recognized at the day -1 average.
4.2.2.2

Neurological severity score (NSS)
The neurological severity score (NSS) is a common neurological scale used to

determine deficits post-TBI and stroke injury. A total of eight tests were performed on
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each mouse. The tests included (1) startle response, (2) hindlimb flexion, (3) seeking
behavior, (4) balancing on a 0.5 cm square beam, (5) balancing on a 0.5 cm rod, (6)
walking 30 cm on a 3 cm beam, (7) walking 30 cm on a 2 cm beam, and (8) walking 30
cm on a 1 cm beam.13 If the animal showed sufficient abilities to complete the objective,
they were given a 0. If the mouse could not complete the task, they were given a 1. At the
end of the tests, the scores were tallied on the record sheet depicted in Figure 4-1.

Figure 4-1: NSS data record sheet.
Students administered NSS tests without knowledge of their treatment groups.
These tests were conducted on days 2, 5, and 7 after injury or sham injury. The mice with
a higher score showed more impairments than the mice with lower scores. For example,
if a mouse had a score of 5, it had vestibulomotor impairments indicative of a moderate
brain injury. On the other hand, a mouse with a score of 0 had no observed impairments,
which was typical of sham-injured mice. NSS testing data were collected on days 2, 5,
and 7 post-injury.13,86,91 Refer to Appendix B for the full form.
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4.2.2.3

Open field (OF)
Open field (OF) test was performed to measure anxiety levels via locomotor

behavior in mice post-injury and treatment. This test was performed 7-days post-injury,
the day of harvest, to gauge long-term impairments from injury/treatment. As prey
animals, mice have an aversion to open brightly lit areas, but they also have an instinct to
explore their area. This conflict in behavior gives rise to anxiety.92 Animals would be
inclined to explore their environment. Theoretically, a healthy mouse travels more
distance and enters the center area more often. If impairments have occurred that cause
the mouse to feel more anxiety, it does not venture into the middle of the arena as much,
or it would refuse to move at all. In this manner, we are observing the distance of
movement in the arena.92
For the OF test, a mouse was placed in the middle of a square arena, a 30 cm x 30
cm box with 25 cm walls in a brightly lit area with an overhead camera recording
movement. The box was painted white to better contrast with the dark fur of the C57BL/6
mice used in this study. The mouse was left to explore the area for 5-minutes with no
distractions. After 5 minutes, the mouse was placed back in its caging. The analysis was
performed using a plugin for ImageJ, and during this phase, researchers worked with
blind treatment groups. The total distance traveled was used as the outcome measure.93,94
In the Open Field Test shown in Figure 4-2, the mouse was introduced into a
brightly lit arena, and its movement was recorded using an overhead camera. The
movement and location of movement of the mouse in the field were tracked and analyzed
using the ImageJ plugin by researchers blinded to the treatment groups.
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Figure 4-2: Open field (OF) test. The mouse was introduced into a brightly lit arena and
its movement was recorded using an over-head camera. The movement and location of
movement of the mouse in the field was tracked and analyzed using ImageJOF plugin, by
researchers blinded to the treatment groups.
4.2.2.4

Novel object recognition (NOR)
Novel object recognition (NOR) is used to test for memory impairments and was

performed the day of harvest to determine memory impairments post-injury in treated and
untreated mice. When performed in conjunction with OF, this test does not require a 5minute acclimation period before recording. Two objects of similar size were placed in
adjacent corners of the box. The mouse was then placed in the arena, facing the opposite
of the two objects to avoid prejudice. The arena is the same box used in the open field
test. The mouse was allowed 5 minutes in the area to investigate the objects. After 5
minutes, the mouse was placed back in its home cage, and one of the two objects was
removed and replaced with a different object. The mouse was then allowed five more
minutes to investigate one new or novel object and one old object. The mouse’s
exploration of the objects was recorded for both sessions using an overhead camera with
no interaction from researchers during recording. Due to the limited ability of mice to
discern color, the object's color was not considered relevant. This test was performed to
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investigate memory deficits from the TBI.95 If there were no damage to memory, the
mouse would spend more time with the novel object in the second session than time spent
with the familiar object. It is also understood that mice under inflammatory conditions
show impairments on the NOR test.96 The outcome measure was the number of times the
animal placed its nose on the object.93,94 Figure 4-3 illustrates the test structure. In an
open arena, (A) two objects are placed in adjacent corners, (B) the mouse is placed inside
the arena facing away from the objects and allowed to explore for five minutes. (C) After
exploring, the mouse was removed, and one object was replaced with a different object.
(D) The mouse was then allowed to explore the arena for another five minutes

Figure 4-3: Novel object recognition (NOR). NOR is used to test for memory
impairments. In an open arena, (A) two objects are placed in adjacent corners, (B) the
mouse is placed inside the arena facing away from the objects and then allowed to
explore for five minutes. (C) After exploring, the mouse was removed, and one object
was replaced with a different object. (D) The mouse was then allowed to explore the
arena for another five minutes.
4.2.2.5

Elevated plus maze (EPM)
Mice were placed on an elevated plus maze (EPM) to determine their relative

level of anxiety. This maze comprised a raised platform in the form of a plus sign (+)
with each arm equidistant from the other and of equal lengths. Two arms forming one
part of the cross were open; 25 cm walls enclosed the other two arms.
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The mouse was placed at the neutral zone, an intersection of the closed and open
arms, to perform this test. The mouse was then allowed 5 minutes to explore the maze
with no distractions. Each trial was recorded with an overhead camera. Analysis of the
recordings was performed using ImageJ software by persons blinded to which treatment
group was which.93,94 This test was performed the day before sacrifice.97
Figure 4-4 shows how the EPM maze test was structured. EPM maze was
elevated 50 cm from the ground with four 25-cm arms with 90O angles between them.
Two of the arms had raised sides, and two were open. The maze was painted white to
contrast with the dark color of the mouse fur.

Figure 4-4: Elevated plus maze (EPM). The EPM maze was elevated 50 cm from the
ground with four 25-cm arms with 90O angles between them. Two of the arms had raised
sides, and two were open. The maze was painted white to contrast with the dark color of
the mouse fur.
4.2.3

Harvest
To harvest the mouse brain, each animal underwent cardiac perfusion; the

procedure for harvest was described in detail in Chapter 3.
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4.2.4

Tissue Fixative
The harvested mouse brains were left in formalin for 15 hours. After this time, the

brain was rinsed in PBS before being fully saturated in a 30% sucrose solution (PBS).
After 2-days, a suffused brain sinks into the sucrose solution. When saturated with
sucrose, it was then safe to flash-freeze the brain and store it at -80°C until it was needed
for subsequent slicing for IHC or other assays.
4.2.5

Brain Slice Processing

4.2.5.1

Slicing
The mouse brains were thawed on ice and divided into hemispheres before

refreezing for slicing. Slicing was performed on a Leica cryostat CM 3050S at LSUHSC
in Shreveport. The tissue was held at an optimal cutting temperature, mounted using a
TissueTek OCT compound, and cut into 40-µm thick sagittal sections. These sections
were stored in a glycerol-based cryoprotectant in 96-well plates.98
4.2.5.2

NISSL stain
A NISSL stain was performed on slices derived from the various treatment groups

to visualize the cell bodies. The slices were first mounted on charged slides and allowed
to dry for 3-4 days at room temperature. The slices were then hydrated in dH2O for 6minutes. A thionin working solution composed of 0.25% thionin in sodium acetate and
acetic acid was then added directly to the slide using a transfer pipette and allowed to
incubate at room temperature for 30-minutes. This stain was rinsed using dH2O for 3minutes. The slices were further rinsed in 70%, 70%, 95%, and 100% solutions of
increasing ethanol concentration for 3-minutes at each concentration. The staining was
incubated in xylene for 8-minutes before adding Permount and a coverslip.99
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4.2.5.3

IHC stain
The IHC staining protocol consisted of using Abcam ab7260, a glial fibrillary

acidic protein primary antibody derived from rabbits. The protein	
  was used with a
biotinylated anti-rabbit secondary antibody from Vector Laboratories.
Sagittal 40-µm thick slices were used for IHC staining. After preliminary staining
using a stereological method, the sections were selected based on the inclusion of desired
loci. Slices were stored in an IHC World cryoprotectant and, before staining, were
washed in 0.01 M PBS.98 Endogenous peroxidase activity was blocked by using Abcam,
ab64218,	
  a hydrogen peroxide blocking solution, for 20 minutes. The peroxide solution
was washed away using 0.01 M PBS, and then a 4% NGS, 1% BSA in PBST proteinblocking solution was added. This solution was washed off, and the cells were
permeabilized using phosphate-buffered saline with Triton X-100 (PBST).
As recommended by the supplier, the primary antibody was added at a 1:1000
dilution and incubated on the sections at 4ºC overnight while rocking. The following day,
the slices were washed in room temperature PBST before the Vector Laboratories 1:200
dilution of anti-rabbit biotinylated secondary antibody was added. These slices were
incubated in the secondary antibody for 2-hours at room temperature with shaking. The
slices were washed again in PBST, and RTU A.B.C. PK7100 vector stain was added
during another 2-hour incubation. A ready-to-use RTU A.B.C vector stain kit utilized
avidin/biotinylated enzyme complex to increase staining specificity of biotinylated
molecules when used in conjunction with the VECTASTAIN ® substrate color
developer.
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The developing solution was washed off using PBST and then PBS before the
Vector SG substrate color developer was added. The solution was made using 3-drops of
Reagent 1, and 3-drops of Reagent 2 added to 5 mL PBS at 0.01M. Enough solution to
cover the slices was added to each well. After two minutes, the color had developed
sufficiently, and the slices were rinsed in PBS to stop the reaction. Sections were
processed simultaneously and monitored closely to avoid overdevelopment. The slices
were mounted on Premiere premium charged slides and allowed to dry overnight. The
following day the slices were optically cleared using progressive dehydration steps.
Slices were submerged in ethanol (EtOH) for 2-minutes per step in the following
sequence: 50% EtOH, 75% EtOH, 95% EtOH, 100% EtOH and 100% EtOH. They were
finally submerged in xylene for 15 minutes before coverslip and Permount were applied.
The color developer marked GFAP with a dark blue color visible on a microscope, then
converted to black (with white background) using ImageJ.
4.2.6

Imaging and Image Analysis
Imaging was performed on an AmScope mounted microscope camera on an

AmScope compound microscope. Images were taken of the 40 µm sagittal section at
4.5x, 10x, 20x, 40x, or 100x magnification on brightfield and processed with ImageJ or
combined using Microsoft Image composite editor (ICE) software. Each image was
converted to an 8-bit black/white TIFF file, and the stitched sections were converted to
black and white.
4.2.6.1

Whole slice analysis
Images were first taken at 4.5x magnification of sections from TBI-vehicle and

sham-vehicle mice to identify regions of interest (ROIs), showing apparent differences in
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astroglia activation. The images were auto stitched using Microsoft Image Composite
Editor. Images were viewed, and ROIs were examined using established criteria.
4.2.6.2

ROI determination
ROIs were chosen by comparing color development between the TBI-injured and

the Sham-injured whole-stitched sections. Ten regions were selected and re-imaged using
a 20X microscope objective lens. The mean intensity of the ROIs was measured using
ImageJ. The group with the largest difference in mean intensity was used to analyze
injury and treatment groups further.
4.2.6.3

External capsule imaging
The ROI with the greatest difference in astroglia activation, as determined by

mean intensity, between sham-vehicle and TBI-vehicle-treated mice was the external
capsule, and dorsal region of the striatum referred to as the caudate-putamen. From the
five treatment groups listed in Table 4.1, three animals per treatment group were selected
and used. One slice was selected per brain in roughly the same distance lateral to the
midline, and the same brain structures were included in each for a total of 15 slices. All
15 slices of the cohort were imaged on the same day in the same session to limit
variability.
Figure 4-5 shows the images were taken by following the corpus callosum to the
rostral region, where it changes direction. The camera frame was then moved down into
the caudate-putamen until the fiber tracts of the corpus callosum were just out of view in
the top left-hand corner. This area is called the external capsule of the caudate-putamen.
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Figure 4-5: Location of striatum images. The images were taken by following the corpus
callosum to the rostral region where it changes direction. The frame of the camera was
then moved down into the caudate putamen until the fiber tracts of the corpus callosum
were just out of view in the top left-hand corner. This area is called the external capsule
of the caudate putamen.
4.2.6.4

Mean intensity
The external capsule 20X images were opened on ImageJ and changed to 8-bit

black/white TIFF files. The images were inverted, and artifacts were removed using the
freehand selection tool—the outcome measurement parameters of area, mean gray value,
and median. Results were copied and pasted into Microsoft Excel for statistical analysis.
The mean intensity and median intensity values were compared to determine the results,
then recorded.
4.2.6.5

Cell count analysis
Striatum 20X 16-bit images were opened in ImageJ and converted to 8-bit. The

images were inverted, and the artifacts were removed and deleted using the freehand
selection tool. The threshold was set, so the cell soma on non-reactive astrocytes was
included. The diameter of the non-reactive cells was measured using the line and measure
commands on ImageJ and was used as the particle size limit on the “analyze particle”
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menu. Some non-reactive cells may not be included on this threshold, and as a fail-safe,
the images were analyzed manually. The same threshold limits were used for every image
in a single cohort to maintain consistency.
A total cell count was determined using the particle analyzer and counting
particles sized “9-infinity” (Figure 4-6). The three sham-injured slice images were
analyzed first, and the size of reactive cells was determined from the average cell size of
the total cell count. Images were manually checked to ensure cells not included in the
software analysis were included in the cell count. Percent reactivity was determined from
these values.
Figure 4-6 illustrates how the threshold was determined per cohort by adjusting
the upper and lower limits on the threshold menu. The limit was chosen when the cell
soma of non-reactive cells was covered with the “red threshold indicator.” Due to the
drastic difference in the size of reactive and non-reactive cells, some smaller non-reactive
were not counted by the threshold option. These cells were counted manually and added
to the total cell count.
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Figure 4-6: Threshold for cell count.
4.3
4.3.1

Behavioral Test Analysis

4.3.1.1

Rotarod

Results

Rotarod testing was performed on days -3, -2, -1, 2, 5, and 7. There was not a
statistical difference or trend observed to distinguish the sham-injured from the
TBI-injured. No distinction could be made between treatment groups to attribute
therapeutics with an increase/decrease of motor skill.
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4.3.1.2

Neurological severity score (NSS)
NSS scores were collected on days 2, 7, and 14 post-injury or sham-injury (Figure

4-7). The trend suggested an overall decrease in neurological impairments in all but the
TBI + IN PgP-Rm + IP Vehicle when Day 5 and Day 7 are compared with Day 2.
Because of the wide distribution of the collected data, no statistically significant
difference was observed between the groups. A single-factor ANOVA was performed
between the treatment groups, Day 2 data had a p-value of 0.1, Day 5 data had a p-value
of 0.5, and Day 7 data had a p-value of 0.1.
Figure 4-7 reflects the NSS measurements of days 2, 5, and 7. These data were
used to determine the progressive effects of the secondary injury. The animals were
scored from 0-8; an animal achieving an eight would have the most neurological deficits.
There was no statistically significant difference between each of the treatment groups.
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Figure 4-7: Neurological severity score. (n=3; p-value>0.05).
4.3.1.3

Open field (OF)
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An increase in anxiety is a related insult from TBI.95 To test this hypothesis, the
mice were subjected to an open field (OF) test where the distance and time spent in the
center of the arena were measured. The results of the OF test are reported in Figure 4-8.
The total distance test had a p-value of 0.68 between the treatment groups. The time spent
in the center of the arena had a p-value of 0.31. There was no observed trend or
statistically significant difference between the treatment groups in either test after 7-days
post-injury. The distance was tracked and measured using ImageJ software for the total
distance traveled, and the time spent in the center of the arena was timed.
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Figure 4-8: Total distance traveled and time spent in the center on OF test. Animals
underwent an open field (OF) test (n=3). There was no statistically significant difference
between the treatment groups for either test. (p-value>0.05).
4.3.1.4
Novel object recognition (NOR)
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The number of entries into a specific zone around each object was recorded. The
number of times the mouse investigated the novel object was divided by the total time the
mouse investigated either object and multiplied by 100. This value was the percent of
time spent with the novel object recorded in Figure 4-7. When the value was above 50%,
such as sham (non-treated), IN PgP + IP vehicle, IN PgP-Rm + IP vehicle, IN PgP-Rm +
IP mino, the animal visited the novel object more frequently (n=3). Mice were test days
post-injury. A single factor ANOVA was run, and the p-value was 0.19. There was no
statistically significant difference between the treatment groups (see Figure 4-9).
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Figure 4-9: Percent time spent with novel object. (p-value>0.05; n =3 per treatment
group.
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4.3.1.5

Elevated plus maze (EPM)

4.3.1.5.1

Percent time on open arms

The percent of the time on the open arms was measured and compared between
the treatment groups. Animals were tested on EPM on day six post-injury. A single factor
ANOVA was run, and the p-value was 0.42. A t-test was performed on untreated TBI and
untreated sham, and the p-value was 0.02; however, due to the large variation in the
treatment groups, there was no significant difference between the treatment groups (see
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Figure 4-10).
Figure 4-10: Percent time on open arm. (n=3 per treatment group). (p-value=0.42).
4.3.1.5.2

Percent entry on open arms

The percent of entry was measured to determine how many times each animal
entered the open arms of the EPM (Figure 4-11). The mice were treated with the various
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treatment groups post-injury and compared to the TBI and sham-injured animal results.
These recordings were taken on Day 6 post-injury. There is a difference between the
number of times the sham-injured mouse entered the open arm and the injured mice (p =
0.072). However, a single factor ANOVA determined no statistically significant
differences between the treatment groups when evaluating the percent entry into the open
arm (p-value= 0.31).
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Figure 4-11: Percent entry to open arm. (n=3). There were (n=3; p-value>0.05).
4.3.2

GFAP Analysis

4.3.2.1

Selecting regions of interest
As visualized using a GFAP IHC stain, Astrocytes express a large morphological

change when they become reactive. As shown in Figure 4-12, the cell soma increases in
size, and the end foot processes increase in thickness and increase expression of GFAP.
Areas in the sections can be matched by comparing image intensity. An increase in
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GFAP expression can be identified by a higher intensity when compared with other
regions. When activated, the cells express a higher amount of this protein (GFAP) which
can be observed by measuring the intensity of specified regions. Analyses were
performed comparing mean intensity and cell soma diameter. The base images were
acquired using an AmScope microscope and camera with a 100x objective. The insets are

Reactive

Non-reactive

the cropped and enlarged images of the reactive and non-reactive astrocytes.
Figure 4-12: Reactive and non-reactive astroglia cells. Astroglia undergo a large
morphological change when they become reactive. The cell soma increases in size and
the endfoot processes increase in thickness. These astrocytes were stained using an
antibody against GFAP. When activated the cells express a higher amount of this protein
(GFAP) which can be observed by measuring the intensity of specified regions. Analyses
were performed comparing mean intensity and cell soma diameter. The base images were
acquired using an AmScope microscope and camera with a 100x objective. The insets are
the cropped and enlarged images of the reactive and non-reactive astrocytes. Scale bars
are 10 µm.
To select a region of interest (ROI) that would optimally show differences
between treated and untreated mice, full sagittal sections stained with anti-GFAP
antibodies were stitched together from high-magnification images. Full sagittal sections,
one medial and one lateral were taken from a sham-injured and a TBI-injured mouse.
Each mouse received vehicle treatments used to identify a suitable region for full analysis
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of all animals in the study (Figure 4-13). These images were used to determine optimal
ROIs with the greatest difference between injured and non-injured animals. Multiple
regions were evaluated from four sections, two sham-injured and two TBI-injured. The
areas being compared included the hippocampus, dentate gyrus, thalamus, striatum, deep
motor cortex, superficial motor cortex, superficial and deep sensory cortex, cortex under

injury site, and the substantial nigra.
Figure 4-13: Whole slice image 4.5x magnification. These images were taken using a
4.5x objective and stitched together using Microsoft image composite editor. The images
show a medial (A & B) and more lateral (C & D) depiction of mouse brains that received
an injury and not treatment and received no injury and no treatment. A & C show
sections from animals that received a TBI, and B & D show sections that received a sham
injury. E shows the regions picked for further analysis. (scale bar = 1 mm).
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The lateral slices did not have a deep motor cortex but were identified by
comparing markers on the sections to a mouse brain atlas of sagittal sections. As a result,
the deep motor cortex is missing from Figure 4-14. These images were taken on the same
day, and the intensity was comparable. The analyzed images are seen in Figure 4-14 A.
The quantitative difference between sham-injured and TBI-injured using the mean
intensity was illustrated in the histogram in Figure 4-14 B. These regions were calculated
using ImageJ and compared using their mean intensity. As seen in Figure 4-14 B, the
striatum had the largest difference between sham-injury and TBI-injury models. A star
indicates this difference. In these preliminary results, the researcher identified the most
optimal area for further analysis using the GFAP stain.

A.
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Mean intensity variations between TBI-injured and
Sham-injured animals
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Figure 4-14: (A) Comparison of 10 regions of interest. Each column represents one of
B.
the four slices in Figure 4-13 analyzed for preliminary results to determine the ROI (two
slices from TBI injured animals and two slices from sham injured animals). The lateral
slices did not have the deep motor cortex presence. (B) The mean intensity was measured
from each of these images and further compared for a single specific ROI. Analysis of
mean intensity was performed using ImageJ. The striatum had the largest significant
difference between TBI-injured and sham-injured animals. Images were taken at 10x
magnification. (n=2).
Individual sections from the five treatment groups were selected that contained
the same location of the external capsule (n=3). These were stained using the anti-GFAP
antibody and imaged. The mean intensity and median intensity were recorded. The
artifacts in the images obstructed the mean intensity reading, and the median intensity
value was used in its stead. Median values were used instead of mean intensity due to the
interference of the artifact. These values were averaged together per treatment group to
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result in the graphical data, and the error bars represent the standard error of each data
set. A single factor ANOVA was performed to compare treatment groups, and no
statistically significant difference exists between the treatment groups. Median intensity
results were graphed in Figure 4-15. It was determined that the TBI and sham treatment
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groups differed (p = 0.067), but a single factor ANOVA showed no statistical difference
between the treatment groups (p=0.081).
Figure 4-15: Median intensity values. Median values were used instead of mean intensity
due to the interference of the artifact. These values were averaged together per treatment
group (n=3) to result in the graphical data. The error bars represent the standard error of
each data set. A single factor ANOVA was performed to compare treatment groups. No
statistically significant difference exists between the treatment groups. (p-value= 0.081).
Astroglia transforms in a well-known drastic morphological change when
activated. A short procedure was implemented to determine the exact measurable soma
diameter for these specific sections; the diameter was measured using the ImageJ
measuring tool. In four sections, a total of 24 cells, three active and three nonreactive
astroglia, were identified based on observed differences in morphology. A line was drawn
across the soma in GFAP stained sections and measured by ImageJ. The soma diameter
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was significantly different between the reactive and non-reactive astroglia, consistent
with previous reports of astroglial reactivity.35,36 When setting the threshold particle size,
these values were used to identify individual reactive and non-reactive cells in the 20x
images taken on the AmScope microscope. The procedure was performed to increase the
accuracy of ImageJ input values when performing a cell count. The average diameter of a
non-reactive astrocyte was calculated as 8.936 µm with a standard error of 2.56 µm. The
average diameter of a reactive astrocyte was calculated as 31.28 µm with a standard error
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of 7.88 µm, p-value=1.6E-6. It was possible to determine a more accurate cell count
using the threshold application and particle size analyzer on ImageJ (see Figure 4-16).
Figure 4-16: Diameter of reactive and non-reactive astroglia. Diameters were measured
using the measuring tool in ImageJ (a line was made across the cell body and measured).
Twenty-four values (12 reactive and12 non-reactive) were arbitrarily picked and averaged
and shown above. Error bars signify the standard error of the groups. There is a
significant difference between the two groups. The measurement was performed to
increase the accuracy of particle size for use with the particle analyzer in ImageJ to
determine a more accurate cell count (p-value<0.0001).
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Reactive cells were counted and compared between treatment groups. A single
factor ANOVA was run showing a difference between some of the treatment groups
(p= 0.001). There was a statistical difference between the sham-injured animals that
averaged 10% reactive and the TBI-injured nontreated animals that averaged 30%
reactivity (p-value = 0.028). The sham-injured and TBI PgP treated (p=0.050), TBI
untreated and TBI PgP treated (p=0.031), and TBI untreated and TBI PgP-Rm treated
(p=0.028) all had statistically significant differences between the treatment groups (pvalue>0.05). TBI PgP-Rm treated and the TBI PgP-Rm, and mino treated showed no
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significant difference between the treatment groups. Figure 4-17 displays this data.
Figure 4-17: Percent reactive cells in the striatum. A single factor ANOVA determined a
statistical difference between the treatment groups (p-value=0.001). The treatment groups
with asterisk showed statistically significant differences in reactive cells in the striatum
compared with the TBI-injured nontreated animals.
The sham-injured and the TBI-injured (untreated) p-value = 0.028
The sham-injured and TBI (PgP treated) p-value=0.050
TBI (untreated) and TBI (PgP treated) p-value=0.031
TBI (untreated) and TBI (PgP-Rm treated) p-value=0.028
(n=3)
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4.4
4.4.1

Discussion

Behavioral Test
Behavioral tests were incorporated to distinguish levels of sensory, motor, and

cognitive deficits between treatment groups. The projected hypothesis for each test
presented that if the treatments provided a therapeutic effect, the behavioral test would
significantly differ from the TBI untreated animals. The sham-injured (untreated) animals
were expected to have a small margin of deficits due to the animals' intensive surgical
operation (craniotomy), but with no TBI, they were expected to perform significantly
better than the injured mice.100 Using the model of diffuse moderate TBI, there were no
significant differences in OF, NOR, and EPM performance.
4.4.2

Histology
For the histological evaluation of events in the brain, a GFAP antibody stain was

incorporated to visualize astrocytes astroglia. The first objective was to determine an area
visually differing between the sham-injured and TBI-injured animals. For this, ten
regions of GFAP stained slices were compared. Of those ten, the external capsule of the
striatum, referred to as striatum, was deemed to have the largest proclivity for injury.
This area is heavily populated with axonal tracts and is relevant when observing diffused
axonal injury (DAI). DAI occurs due to the undulations of the neuronal tissue when
shearing of long axonal tracts occurs.21 This area was previously observed with the
implantation of a GRIN lens to observe the effects of minocycline on the development of
varicosities.13
Once the ROI was identified, the difference between reactive astroglia and nonreactive astroglia was determined. Because of their drastic size difference, the distinction
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between the stained cells was deemed discernible. The two orders of analysis consisted of
determining the intensity and cell reactivity. The slices were picked using a stereological
technique to ensure comparability between slices. Also, the same protocol for imaging
was performed to negate any differences. The mean intensity of the images was taken.
Due to the large difference in the mean intensity values, the median value was used.
Artifacts were cropped out of the images, but a large variation in mean value suggested
that many artifacts remained. The mean value represented the bulk of the measured
values, negating the highest and lowest artifacts. The image intensity proved no statistical
difference between the treatment groups.
A power analysis was performed using the data from intensity-staining and the
percentage of cell reactivity to determine the optimal sample size to detect an effect with
the desired significant difference from the treatment groups. It was calculated that an
optimal sample size of six would yield a suitable outcome of the effect of the treatments
tested here. The methods and the results of the power analysis are recorded in
AppendixºD.

CHAPTER 5
GABA/GLU BIOSENSOR DEVELOPMENT FOR POTENTIAL
STUDY OF NEURODYSFUNCTION
5.1
5.1.1

Introduction

GABA/GLU: Excitatory/Inhibitory Neurotransmitters in Brain
Gamma-aminobutyric acid (GABA) and Glutamate (GLU) are the major

excitatory and inhibitory neurotransmitters in the brain. The homeostatic balance of the
excitatory/inhibitory (E/I) system is due to dynamically controlling the levels of GLU and
GABA under varying conditions. Disruption of this activity causes major bioelectrical
dysfunction.101 An excess of GLU leads to excitotoxicity which is known to cause seizure
activity.66,69 Conversely, a deficiency in GABA is also attributed to seizures.69,102
5.1.2

GABA/GLU with TBI
TBI can cause extensive damage to the E/I system. TBI causes damage to

neurons, axonal shearing, depolarization, excitotoxicity, and inflammation.2,3 This
damage relates to changes in concentrations of extracellular neurotransmitters, receptor
location and population, and cell reactivity.65 The damage disrupts the E/I system, such as
an increase in extracellular GLU, resulting in cellular excitotoxicity or extensive
stimulation of nervous receptors due to a pathological high/imbalanced concentration of
extracellular neurotransmitters. One study conducted over 3 years on a specific
population showed that 4.4% of mild TBI patients developed post-traumatic epilepsy
(PTE).103
76
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Although rare, PTE, characterized by two or more unprovoked seizures post-TBI, can
develop years after the injury.2,3,104 Isolated seizure activity can also occur without the
development of epilepsy.
5.1.3

Real-Time Sensor Development
GLU/GABA levels are most commonly measured by microdialysis, which has a

very poor temporal resolution, generally on the order of minutes. With the development
of biosensors, real-time recording is possible, providing sub-second resolution.
Biosensors use an enzymatic reaction in which one of the reaction products is electrically
active; this product is recorded through electrodes under the enzyme coating—the
resulting current scales with the chemical concentration.
One such method, described in the development of the silicon microelectrode
arrays (MEAs), is described here. MEAs have separate platinum (Pt) electrodes that are
each coated to detect (1) GLU, (2) GABA and GLU, and (3) interferent molecules called
the sentinel channel.71 GLU and GABA are not electrically charged molecules. They
cannot be detected directly by electrodes; however, endogenous enzymes break down the
neurochemicals and produce H2O2, electrically charged.
By using enzymes specific to GLU and to GABA and that separate into H2O2, the
concentrations can be calculated indirectly from the level of current produced by H2O2 at
the Pt electrodes. One Pt electrode is coated with glutamate oxidase, the GLU channel,
which produces α-ketoglutarate and H2O2.105 To detect GABA, both GABase and
glutamate oxidase are applied to another Pt electrode, the GABA channel.72 Notably, the
α-ketoglutarate produced by glutamate oxidase on the GABA channel is a substrate for
the GABAse reaction that produces H2O2 from the breakdown of GABA. The electrical

78
current from the GLU probe coated with only glutamate oxidase is subtracted from the
GABA channel to render the GABA current.72 A size exclusion layer of mphenylenediamine (mPD) was also incorporated on all the probe sites to reduced random
amino acids and larger molecules from interacting with the sensor.72
The sentinel site has the same coatings as the GABA and GLU channels but
without any enzymes. The enzymes are replaced with albumin to maintain the same
diffusion rate to the Pt electrode and measured other electrically charged molecules in the
environment. Its current is subtracted from the GLU and GABA channels to mitigate the
otherwise confounding influence of electrically active interferent molecules on GLU and
GABA detection, which increases the specificity of the biosensor channels. Calibration
curves for each channel are used to convert electrical current to GLU and GABA
concentrations. The same coating and analysis process can be combined into microwires
using Teflon coated 127 µm diameter Pt wires.72
Glu(E) + H2O + O2 → α-ketoglutarate + NH3 + H2O2(E)
GABA + α-ketoglutarate →SSA + GLU(GABA)
GLU(GABA) + H2O + O2→ α-ketoglutarate + NH3 + H2O2(GABA)

(Eqn. 1)
(Eqn. 2)
(Eqn.3)

Abbreviations are as follows: Glu(E) = environmental GLU, H2O2(E) = H2O2 from GLUE,
SSA=Succinic semialdehyde, GLUGABA = GLU from GABA oxidation,
H2O2(GABA)=H2O2 from GABA two step reaction.
Figure 5-1: GABA and GLU probe surface reactions. Equation 1 depicts the reaction on
the GLU. In the presence of glutamate oxidase, GLU breaks down into α-ketoglutarate,
NH3, and H2O2. The platinum electrode oxidizes H2O2 when in contact releasing two
electrons creating a measurable current. GABA can be measured using GABAse and αketoglutarate (Eq2) but adding α-ketoglutarate in vivo is unsuitable. Due to this, the
GABA probe is coated with glutamate oxidase and GABAse. In Eq 1, we see αketoglutarate is a product of the reaction. In Eq. 3, α-ketoglutarate is produced in a high
enough concentration to interact with GABA and in the presence of GABase produce
H2O2.72
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Alternative research with the technology defined by MEAs is geared towards
nanomanufacturing the electrode sites on shanks such as ceramic or silicon. The ceramic
shank uses the same technology as the MEAs, but in the microwires, it has Pt electrode
sites microfabricated on a ceramic shank. This design is shown in Figure 2-10 and was
implanted in rat hippocampal cells where it showed an adequate recording of
GLU/GABA signals. Issues with this design included the distance between electrodes and
the size of the shank. The distance of the electrode sites eclipsed the size of specific loci
in a rat brain, making the region analyzed for GABA slightly different than the loci
analyzed for GLU.106 Three sets of electrodes were fabricated on the shank with 1 mm in
between each set of paired electrodes. Each pair of electrodes were spaced 100 µm.106
The implanted shank was also relatively bulky, making it detrimental to the surrounding
tissue.106 The ceramic shank-style probes also show the importance of flexibility.
Although functional, in live animals, the rigid structure was susceptible to breaking while
the rat was in housing.106
5.1.4

Si Probe Development
The silicon or Si probes were microfabricated by Dr. Nicolaie Moldovan from

Alcorix and used a silicon substrate base for Pt. The Si probe consists of a printed circuit
board (PCB) with gold metallization on which the micro-manufactured silicone shank
was mounted using epoxy glue. The 0.2 mm x 0.2 mm shank design was manufactured to
have a slim profile and a minimally invasive design. Surgical implantation of any device
caused damage to the neural tissue that is capable of affecting neurochemical activity.
The compact design theoretically reduces tissue damage during implantation, which
would reduce the inflammatory response to the surgery. The use of a silicon shank also
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implements the use of an On-Demand In-situ Calibrator (ODIC). The ODIC has a
microfluidic channel capable of performing in situ sensor calibrations, thereby increasing
detection accuracy. The ODIC also allows for the possibility of future drug studies.70
Each electrode was fabricated to be 50 µm from the outlet pore. In this research, the
implantability of this compact design was tested (see Figure 5-2 and Figure 5-3). It was
expected to allow for greater accuracy to implant in CA1 cells of the hippocampus.70

Figure 5-2: Si Probe Dimensions. The silicone-based shank is 10 mm long and 0.2 mm x
0.2 mm. Platinum (Pt) electrode sites are spaced 50 µm from the outlet pore (center
point). The microfabricated outlet pore allows for real-time calibration by
microinjections. The slim design is aimed to decrease damage caused to neural tissue
when implanted. Image curtesy of Dr. Moldovan (Alcorix).
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Figure 5-3: Si Probe. a) magnified probe tip b) Si probe shank c) Final device with Si
probe mounted on the printed circuit board (PCB) with the microfluidic connectors
attached d) full-length view of unconnected Si probe. (1) Pt microelectrode (2) insulated
leads; (3) Pore opening of the microchannel (4) coated microfluidic channel (both 3 and 4
are a part of the ODIC) (5) probe shaft (length = 1 cm), (6) electrical connection pads for
wiring (7) Si handling board (8) inlet pore opening of the microfluidic channel (inlet for
the ODIC system) (9) guide for attaching ODIC system, (10) Si probe shank, (11) PCB
with Au circuitry; (12) pin electrical connector, (13&14) capillary tube & microfluidic
connector; (15) microfluidic ferrule glued to probe. Permission granted by Dr. Moldovan
of use of published figures. 70
5.1.5

Hypothesis
The goal of this project is to optimize the surgical implant of the Si probe. A

successful implant can record an in vivo signal from neurotransmitter interaction with the
enzymatic coating. The null hypothesis is that the Si probe biosensor is not functional
after implantation.
5.2
5.2.1

Methods

Animal Housing/Handling
To test probes in vivo, adult male Sprague -Dawley rats were used. The IACUC

committee approved all animal research protocols and humane handling at Louisiana
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Tech University. Rats were ordered from Envigo and housed in a 12-hour light/dark cycle
while given ad libium food and water.
5.2.2

Biosensor Preparation
Dr. Prahbu Arumugam’s lab performed characterization and preparation of the

biosensor coating. The Si Probe was manufactured by Alcorix and shipped to Louisiana
Tech University, where the enzymatic coating was performed in the manner described in
Moldovan et al. 2021.70 The sensitivity of the probe was measured when establishing the
calibration curve in increased concentrations of GLU in PBS. The calibration was
conducted at +0.7V across the platinum (Pt) electrodes versus Ag/AgCl wire at
concentrations of 0 µM, 1 µM, 5 µM, 10 µM, 20 µM, and 40 µM to detect H2O2. The
resultant current (pA/µM) established the calibration curve. As described in later sections,
this calibration curve was used to convert GLU current signal (pA) to GLU concentration
(µM).70 Homeostatic GLU concentrations in vivo rat CA1 hippocampal cells has been
reported to range from 25 nM to 4 µM.107,108
5.2.3

Implant surgery

5.2.3.1

Anesthesia
The rat was anesthetized using 5% isoflurane for 7 minutes at 500mL/min flow

rate using the Somnosuite® low flow isoflurane machine and was administered an
intramuscular dose of ketamine (75mg/Kg of body weight) and dexmedetomidine
(0.25mg/Kg of body weight). Following the dosage administration, the rat was placed in
its home cage until a surgical plane of anesthesia was achieved.
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5.2.3.2

Clearing the connective tissue from the skull
The dorsal skull surgical plane was shaved and cleaned using alternating alcohol

then iodine (this was repeated three times). A midline incision was made on the dorsal
skull extending rostral to the ocular socket and ending ventral to the skull base. Surgical
scissors were used to separate the connective tissue from the epidermis, and a spreader
was inserted to keep the skin retracted from the area. All connective tissue was removed
by scraping, and the site was irrigated with saline and hydrogen peroxide before drying
with clean gauze. At this point, the cleared skull was visible. The site was then cleaned
and dried with 1-2 drops of 75-80% isopropyl alcohol.
5.2.3.3

Location of implantation and surgical screws
The location of implantation was determined using coordinates derived from the

rat atlas regarding bregma. The implant location was calculated to ensure that all Pt sites
were implanted in CA1 of the hippocampus. The coordinates about bregma were lateral
+3 mm, caudal -4.6 mm, and depth 2.5 mm, respectively (see Figures 5-4 and 5-5). The
depth was measured from the pial surface, and a 1.25 mm dental burr was used to drill
the skull. The bore penetrated the skull with special care to leave the pial surface intact.
Three additional boreholes were created arbitrarily for surgical screws to stabilize the
head plate. The three 1.59 mm stainless steel surgical screws from Stoelting Co. were
implanted to stabilize the final head mount.
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Figure 5-4: Location of Si Probe implantation. The atlas images show the area of
implantation. Figure 5-4A illustrated a coronal section, Figure 5-4B denoted the sagittal
section, and the red square denotes a 0.2 mm square in which all four electrode sites were
encompassed. The Si Probe shank was implanted to take readings from hippocampal
CA1 cells. Coordinates were determined using the rat atlas about the location of bregma
on the scale. Figure 5-4B shows a sagittal cross-section of the area. Adapted from Rat
Brain Atlas by Matt Gaidica and used under Creative Commons license.

Figure 5-5: Image overlay of the implantation site. The implantation site was drilled
+3mm (x-axis) and -4.6 mm (y-axis) relative to bregma. The z-coordinate was derived
from the pial surface -2.5 mm. A borehole was drilled just past the skull, leaving the pial
surface intact.
The pial surface was punctured using a 27 G needle and a surgical microscope for
visualization. Care was taken not to disrupt any vasculature visible underneath the pial
surface (see Figure 5-4). Once the insertion area was cleared using fine-tipped forceps,
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the Si Probe was attached to the stereotaxic frame using a bulldog clamp as seen in
Figure 5-3D, aligned, and lowered at approximately 100 µm/min until the implant depth
was achieved. Several methods of protocol optimization are listed in section 5.2.2.4.
5.2.3.4

Implant protocol optimization: Supplemental support of junction
The Si probe (Si probe 1) was coated for GLU analysis only as described in

Figure 5-1, Eqn 1 to test the surgical implantation method. The Si Probe shank was either
reinforced or non-reinforced before implantation. A non-reinforced probe had no
additional support at the junction of the Si shank and the PCB board before implantation.
The reinforced probe had additional dental acrylic added to the junction before the
implant.
The shank of the probe and the adjacent 3-4 mm space were coated in thin layers
with freshly prepared dental acrylic, which came from Ortho-Jet BCA, Lang Dental
Manufacturing Company, USA. A very thin solution of dental acrylic was drawn up in a
1 ml syringe with an 18 G needle. The probe was then placed at the edge of a petri dish
with the shank angled upwards to ensure no acrylic covered the electrode sites. The
solution was slowly dripped onto the junction between the PCB and the shank to fortify
the connective joint and continued until the acrylic accumulated to a thickness of
approximately 0.1 mm. It was then allowed to cure in ambient light. Next, the probe was
implanted at the locations outlined in Figure 5-3 and Figure 5-4. After the target location
was achieved, another thin solution of dental acrylic was added dropwise at the base of
the PCB boards and allowed to drip down, coating the Si shank before landing on the
skull. The reinforcement added additional support, while more dental acrylic was added
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to build up the protective head mount. These were not fully functioning probes but served
to optimize the implantation protocol.
5.2.4

Reference Wire Adaptation During Surgery
The type of reference wire used was an Ag/AgCl wire coated in Teflon. These

wires were protected from the light as they tend to oxidize quickly.109 The purpose of
these leads is to record any signal besides the neurochemical signaling, which can include
ambient signal, movement artifact, and human interference. These recordings from the
reference channel were then subtracted from the neurochemical signal to negate noise.
Before the header used to secure the implant was formed, the probe was
implanted, and the reference wires were attached and lightly coated with dental acrylic—
a two-part version of the reference wire compared to using an intact reference wire for
the probe. The reference wire was attached by wrapping the uncoated end of the wire
around a surgical screw; the Teflon coating was removed before surgery using a scalpel
blade. A small amount, 1-2 drops from a syringe needle of dental acrylic, was applied and
allowed to harden. The acrylic encased the screw and wire, thereby holding it in place. At
this point, a cut Eppendorf tube was added to the assembly. The tube was cut at the 0.7
mL mark to resemble a hollow tube with a cap. This tube was then notched on the
outside, making an uneven surface for the acrylic to incorporate and cause a stronger hold
on the plastic (Figure 5-7). It was then placed on the skull so that the reference wire
protruded through the middle. The use of a capsule as used by this researcher is unique to
this surgery and was not previously utilized. Care was taken not to disturb the Si probe at
this point. A thin solution of dental acrylic was added inside the Eppendorf tube to cover
the skull and screw completely. Approximately 1 cm of the reference wire was covered
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with dental acrylic, with care taken so that the Ag/AgCl wire was not covered past this
point. The outside acrylic support was also built up at this time and covered the probe,
screws, and skull. The two-part reference wire was cut after implantation leaving
approximately 6 cm enclosed in the Eppendorf tube capsule. Before recording, the twopart reference wire was reattached using silver soldering wire. After recording, the wire
connection was broken and stored in the capsule to protect it from the rat. The end of the
reference wire was removed and protected from light between recordings.
After surgical implantation, the rat was awakened using an intramuscular
injection of Atipamezole hydrochloride (1 mg/kg). Rats were housed individually and
monitored for potential post-operative problems.

Figure 5-6: Probe cover. When not in use, the prongs of the PCB are covered to reduce
damage caused by the animal’s grooming and moving around the cage.

5.2.5

In vivo Animal Recording
In vivo recordings were performed 2-hours after surgery and Monday,

Wednesday, Friday for two consecutive weeks. The rats were sedated using 5%
isoflurane at a 500 mL/min flow rate. Once a plane of anesthesia has been achieved, the
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animals were moved from the induction chamber to a nose cone to continue a steady flow
of isoflurane while permitting access to the probe connector. The protective cover was
removed from the prongs on the PCB, and the connection cord and reference wire were
both connected to the FAST-16mkIII® potentiostat for signal recording. Recordings were
acquired for a minimum of 30-minutes with +0.7V biased across the electrodes to
catalyze the oxidation of hydrogen peroxide. Rats were free to move about the cage. The
cable to the FAST system was supported by hand to prevent the rat from chewing on it.
Figure 5-7 shows the black wire and connector in the FAST system. Behavioral activities
were recorded for offline analysis and to note movement artifacts, which were not
analyzed. Recordings were acquired at 1,000 Hz.13

Figure 5-7: In vivo recording set up. Rats were allowed to roam freely in a clean box
with corn husk bedding. They were given food and water ad libitum.
After recording, the rat was detached from the FAST-recording system. It was
then placed back into the isoflurane chamber for light sedation to reattach the protective
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cover over the PCB connector pins. The rat was then returned to animal housing until the
next recording.
5.2.6

Data Analysis
All data analysis was performed at Dr. Prahbu Arumugam’s lab at Louisiana Tech

University. The data was copied from the FAST system into Excel. The recordings were
made at 1000 Hz, so the time was converted to 0.001, 0.002, 0.003. The time and the 4
GLU channels of data were copied to the Origin 9.32-bit software and graphed in a
current (nA) versus Time (sec) plot. Before implantation, a calibration curve was created
to determine the sensitivity calculation (nA/µM). This sensitivity calculation could be
used to convert the current to the concentration of neurotransmitter (µM). The sentinel
channel was then subtracted to negate interferent electrically charged molecules. The
reference wire channel was used in combination with the observed behavior to rule out
any movement or unrelated artifact.70
5.3
5.3.1

Results

Supplemental Support at Junction
Without additional support, the Si Probe junction of the PCB and shank broke

upon the addition of dental acrylic. After the implant location was achieved, the dilute
solution of dental acrylic was added to the surrounding base. The movement of the dental
acrylic into the area of the implanted probe caused a microscopic shift in the shank,
which resulted in the shank breaking off near the header. The buildup of the dental
acrylic could not be changed as it was required to stabilize the entire implant. The Si
Probe with a small amount of supplemental support at the junction was capable of
overcoming the slight pressure of the dental acrylic. The connection was strengthened by
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incorporating the thin layer of dilute dental acrylic to the outside of the probe before the
implant.14 These were not fully functioning probes but served to optimize the
implantation procedures.
5.3.2

Reference Wire
The two variations of the reference wire included: an in-tact reference wire and a

2-part reference wire. These two versions aimed to add more protection to the wire while
used for an awake, alive rat. The 2-part reference wire took over 30-minutes to soldier
before the behavioral test could commence. For these 30 extra minutes, the rate was
under isoflurane anesthesia. The reference wire was not capable of being soldered by
itself and required the use of soldering silver wire to form the attachment. It was difficult
to maintain wire proximity while the sedated rat continued to breathe. The connection
remained brittle, and in two cases, the recording session had to be stopped for the wire to
be re-attached. Data from the two-part wire was measured to be less the 0.1 Hz
(frequency).
The intact reference wire did not require any additional anesthesia. The animal
was sedated with isoflurane; the wire was removed from its housing and attached. Data
recorded from this reference wire was over 0.1 Hz frequency.
5.3.3

Reference Wire Capsule
The reference wire is a point of the potential problem in a living animal. The

reference wire is attached to a screw directly implanted in the skull. The procedure for
this implantation is discussed in Section 5.3.5. Rats are curious animals and investigate
the headgear implant. Also, during normal grooming, they use their paws to clean their
head and face. All these movements could dislodge the reference wire, placing it in front
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of their face and mouth. With the bite force of a rat, they could easily bite through the
reference wire. The reference wire was encapsulated in an Eppendorf tube to stop this
from happening (see Figure 5-8). The tube was cut to make a hollow capsule that could
fit the surgical screw and reference wire. It was also scored to allow for integration of the
dental acrylic and better adhesion when mounted. When the reference wire was not in
use, it was stored safely in the capsule. No damage from the rat was inflicted on the wire
between recordings.

Figure 5-8: Recording set up. The reference wire was encased in a mounted capsule
made of an Eppendorf tube until needed for recording. The reference wire and Si Probe
prongs are connected to the BLACK wire for recording. A small piece of lab tape was
wrapped around the PCB and the cord to ensure a connection.
5.3.4

Ability to Record Neurochemical Signal
The enzyme coating was crosslinked to calibrate the Si probe by leaving it in the

dark at room temperature for 48-hours. It was then tested in a range of GLU
concentrations from 1 to 40 µM solutions (in vitro). This stepwise calibration curve from
the resultant current values attributed to specific concentrations determined the sensitivity
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calculation (nA/µM). The sensitivity calculation was unique to each probe and allowed
for the conversion from current to concentration. The Arumugam lab performed
calculations. A successful implant resulted in a readable current, as listed below in Figure
5-9. These currents were capable of sub-second GLU resolution on the scale of 100s of
nM (see Figure 5-10).

Figure 5-9: Analysis of Si probe recording. Data were recorded from the Si probe in the
form of current. The sensitivity calculation was determined before the probe was
implanted by use of the calibration curve. Images courtesy of the Arumugam lab.
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Figure 5-10: Sub-second resolution of GLU concentration in an awake, free-moving rat.
(A.) illustrated an example concentration/time curve with key features annotated (not
drawn to scale); the rise time (T1→T2) is 100 ms, and the fall time (T3 →T4) is 105 ms.
This image shows the resolution between GLU concentrations at a sub-second interval. In
image (B), we see the sub-second resolution of GLU from the four channels recorded
during a recording session. Although the electrodes coated the same, there was a
difference in recorded concentration that can indicate recording from a different location
((C) variation between channels 1 & 2 and channels 3 & 4). Images adapted from
Moldovan et al. 2020 (permission for use granted by Dr. Moldovan).

94

5.3.5

Protocol Alterations for Surgical Implantation
The surgical implant of the Si probe required several alterations in technique. The

first alteration dealt with the brittle nature of the connection between the PCB and the
shank. Other probes, such as a ceramic shank probe with MEAs mounted, would not have
this issue because the shank and headboard were one connected structure.69 The Si probe,
manufactured to have a less invasive shank, was manufactured separately from the PCB
and had to be connected. This connection was held by epoxy glue added by the
manufactures of the probe. This glue was not substantial enough to withstand the
manipulative forces of the surgical implant., This research showed the importance of reenforcing that junction before implantation to overcome the glue issue (see Section
5.3.1). The re-enforcement encased the junction and a small portion of the PCB and
shank. Using this method in probes used from recording, it was evident that this step did
not detract from the probe's ability to record neurotransmitters in the brain.
5.3.6

Reference Wire
The reference wire was manipulated to protect it from damage from the rat better

while it was awake. Normal grooming from the rat can kink, damage, or break a fully intack wire, affecting the recordable current.109 Rats have an average bite force of 1300g,
which could easily sever an Ag/AgCl wire and their curious nature leads them to
investigate their new headgear after the surgical implant fully.110 By mounting the
Eppendorf tube on the rat’s head, it ensured that the animal would have no interaction
with the wire and save it from unnecessary manipulation between recordings. The wire
was either left intact or cut as a two-part reference wire after implantation. The two-part
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wire proved to be too difficult to reattach before recording sessions. Using the two-part
wire also required the animal to remain under anesthesia while the wire was soldered
longer than necessary. From these findings, it is advantageous to allow the wire to remain
intact while using a large enough capsule to protect it.
5.3.7

Data Record
The current was recorded from an awake and free-moving rat to determine a

successful implant. These recordings in Figure 5-9 showed sub-second resolution
between GLU concentrations comparable to that previously published in microwire
recordings.70,72 The probe could record a low limit of detection, as small as the 100’s nM
range.70 By demonstrating current neurotransmitter recordings, it was shown that using
this surgical implant protocol with the Si probe is a valid method for in vivo recordings.

CHAPTER 6
CONCLUSIONS AND FUTURE WORK
Although capable of reducing the number of new varicosities formed after TBI,
Minocycline takes 14-30 days to have a therapeutic effect.13 Due to the delayed response
of minocycline, the combination of minocycline and PgP-Rm was investigated. Rm has
significant anti-inflammatory effects when investigated in rodent research models;
however, the adverse effects of taking the oral drug leaves much to be desired as a
treatment option for humans. PgP-Rm was previously used to reduce secondary injury in
rat SCI, but the use of the PgP nanoparticle had not been investigated for delivering drugs
into the brain.4 This study showed that PgP could enter the brain by intranasal (IN) and
intravenous (IV) administration routes. These routes of administration offer less invasive
and more efficient methods of drug delivery when compared with direct injections. After
administering IN and IV PgP complexed with a biological reporter, β-gal, in mice,
staining for the reporter confirmed that the PgP nanoparticles were present in various
locations throughout the brain.
The behavioral tests included in this dissertation work were inconclusive. No
statistical difference was observed between the treatment groups in rotarod, OF, NOR
and EPM. It is possible that increasing the number of animals included in the treatment
groups could cause a more distinctive difference between the results of the treatment
groups.
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An increase in the number of animals was supported by a power analysis of
results from IHC staining, but a minimum power of 70% for rotarod, OF, NOR and EPM
would require the addition of 35, 35, 25, and 35 mice respectively; the numbers are
divisible by five due to the five treatment groups. It is possible that the small difference
between the treatment groups at this time point reflects the mice ability to recover
quickly. Earlier recording post-injury may produce more definitive test results. It is
advised to perform OF, NOR, and RPM on Day 2 post-injury as a future aim.
Furthermore, there is a published difference in behavioral results for males versus
females.92,96,97,100 Increasing the number of animals in each treatment group and
performing analysis with sex bias could reduce the large standard deviation observed in
the behavioral test when only comparing females with other females and males with other
males. Alternatively, the large variation within each group could be due to the large
number of researchers that performed behavioral test and variations in animal handling.
In a short drug trial, mice treated with PgP-Rm post-TBI had a lower percent of
activated astroglia than vehicle-treated mice. Astroglia is activated in response to CNS
trauma. Prolonged activation can lead to glial scarring, which acts as a barrier for axonal
regeneration.111 A reduction in astroglia activation can reduce the immune response,
primarily responsible for the secondary injury. The use of intensity to measure astroglia
activation resulted in no statistical difference between the treatment groups. A second test
was then run, analyzing the number of cells visible and the amount of reactive astroglia
as determined by measuring the cell diameter, resulting in an artifact-free method to
compare differences between treatment groups. The test showed a statistical difference
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between the TBI-injured and untreated animals versus injured animals treated with PgP
intranasal and animals treated with PgP-Rm intranasal.
A power analysis was performed on the preliminary data obtained from the
median intensity value and reactive astroglia count in the striatum. This analysis process
was used to determine an optimal population size that results in an increased probability
of rejecting the null hypothesis as it pertains to preliminary data. The power analysis for
the median intensity in the area analyzed for GFAP expression would increase to 95.3%
by including three more animals in each treatment group. The increase means there
would be a 95.3% probability of rejecting the null hypothesis by including that number of
animals. Using 15 animals in the percent reactive astroglia count test had a 97.5%
probability of rejecting the null hypothesis is reflected in the p-value from the single
factor ANOVA performed on this data set. Because of the high power of the percent
reactive count results, the limiting number of animals was determined by the median
intensity. The least number of animals that should be added to each treatment group was
calculated to be two animals per treatment group and would increase the power of the test
over 80%. Increasing each treatment group by three animals would increase the power of
this one test to over 90%. This number of animals would increase the significance
between the treatment groups in all tests performed.
Future work to classify PgP-Rm as a therapeutic for TBI would include a timelapse evaluation of Rm concentrations in the blood, an indirect measure of
gastrointestinal effect as reflected in 14-day and 30-day weight gain/loss, cytokine assays
to measure anti-inflammatory effectiveness, and evaluating other IHC markers of
neurotrauma.
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One of the major issues with using Rm as a therapeutic is the side effect of
gastrointestinal distress. The implications of conjugating it to PgP have not been studied
concerning this side effect. One simple indirect way to measure this effect is to compare
the weight gain and loss of the animals treated with PgP-Rm. The resultant change in
weight coupled with an analysis of systemic concentrations of circulating Rm in blood
samples should provide insight into whether PgP delivery of Rm reduces the amount of
Rm in the bloodstream vs. oral administration. If it reduces the concentration, then
perhaps this will limit the adverse gastrointestinal effects currently limiting this powerful
medication’s clinical use.
Finally, further investigation of other IHC neurotrauma markers will be
performed. These would include Iba1/AF1 (microglia activation and intensity), MAP2
(intensity of structural protein), CREB, and phosphorylated CREB to determine if normal
downstream activity after TBI is rescued with treatment.
GLU signaling is disrupted after TBI, and this is believed to contribute to
neuronal cell dysfunction and apoptosis. After surgical optimization of the Si probe
biosensor, it was capable of recording GLU in awake rats. The surgical optimizations
included reinforcing the junction of the PCB and the shank and adding a capsule to
protect the implanted reference wire. The small amount of epoxy glue originally used was
not substantial enough to withstand the manipulations of the implant. After reinforcement
with dental acrylic, it was capable of withstanding those pressures. The nature of
surgically implanting a biosensor means the exposed portion must be sturdy enough to
withstand the rat’s movements, including grooming and forceful contacts with the cage
sides and drinking tubes. These actions led to the addition of a custom-designed capsule
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to protect the reference wire. Without the reference wire, the biosensor would be
rendered useless for analysis purposes. Further development of this sensor is planned,
including the addition of GABA for simultaneous recording of GABA and GLU.
Proposed changes to the biosensor include reinforcing the junction with a larger
quantity of epoxy and changing the shank length. By encasing the junction before
shipping, the manufacturer would decrease the chance of damage to the probe. The Si
probe shank length was 10 mm, which left approximately 6.8 mm of the exposed shank
covered and supported by dental acrylic. By decreasing the shank size by 4 mm, a total
length of 6 mm, the chance of damaging the probe while implanting in rats could
decrease. By decreasing the shank length to 2.5 mm, the manufacturer could market a
mouse version of the Si probe. These proposed changes would increase the marketability
and impact of the probe for research.

APPENDIX A
DATA RECORD SHEETS
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APPENDIX B
IMAGE INTENSITY ANALYSIS
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To measure GFAP intensity and compare between the treatment groups, images
were taken at 20x magnification in the same area of the external capsule of the caudateputamen from sham-injured and TBI-injured sections. The method to determine this area
of interest was described in Chapter 4. The preliminary evaluation calculated that the
caudate putamen's external capsule had the largest difference in mean intensity between
TBI and sham-injured animals. The statistically significant difference of p = 0.02
between the sham-injured and the TBI-injured animals determined that this method could
be utilized for comparing treatment effects on this cellular marker of inflammation.
Figure B-1 depicts the mean intensity calculation with raw data obtained by
analyzing TBI-injured and sham-injured mice sections. The mean intensity was measured
using ImageJ, and the values are present in Table B-1, and the summary data is presented
in Table B-2. These values were then averaged together, and the standard error
determined the error bars. Data show a statistically significant difference between the
mean intensity of TBI versus SHAM injured slices. Due to the significant difference
between TBI and SHAM using this method, this test was used to analyze the treatment
groups. A one-tailed t-test was performed on the data for a P-value of 0.02. The
individual animals used are listed in their perspective injury group. Preliminary data
illustrate a significant difference between the untreated animals, sham and TBI, that could
be utilized when comparing therapeutic effect.
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Mean intensity

Mean intensity of striatum images from TBI
and sham-injured mice
150
100
50
0
TBI

SHAM

Treatment groups

Figure B-1: Comparison of the intensity of GFAP stained sections. To determine the
methodology for comparison of intensity of GFAP stained sections, a region of interest
was determined (section 4.3.1.1). The preliminary step to compare these sections was
performed with 2 sham injured untreated and 2 TBI injured untreated mice. The mean
intensity was measured using ImageJ and the values are present in the Table B-1. These
values were then averaged together, and the error bars were determined by the standard
error. This shows a statistically significant difference between mean intensity of TBI
versus sham injured slices. Due to the significant difference between TBI and sham using
this method, this test was used in the analysis between the treatment groups. A one-tailed
t-test was performed on the data for P value of 0.02.
a
mean value after removal of artifacts
SE = standard error
Table B-1: ImageJ Raw Data
TBI
184
186

Sham
191
189

Area
3366912
3366912
SE=
Average
Mean=

Mean
116
127
8.2

Area
3366912
3366912
SE=
Average
Mean=

Mean
59
79
13.8

Min
0
23

Max
255
255

Median
107
107

Min
14
0

Max
255
255

Median
54
63

121

69
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Table B-2: Summary Data
Striatum
SE

a

TBI
121
8

Sham
69
14

Image analysis was performed using ImageJ; the images were first converted to 8bit black/white images (see Figure B-2, Panel A). They were then inverted to render a
black background and white stain (see Figure B-2, Panel B). The inversion lets the
software measure the intensity of a white cell compared to the black background and
allows the measurement of cell intensity in which higher intensity values represent higher
levels of GFAP. Finally, the images were cropped to remove artifacts (see Figure B-2,
Panel C). The measurements were made using the “measure analysis” function of ImageJ.
The measured values included: animal identification, image area, mean pixel intensity,
standard deviation, mode, minimum, maximum, median, and % area (see Figure B-2,
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Panel D.

Figure B-2: Image analysis of striatum intensity stained with GFAP. (Panel A) The
images were first converted to 8-bit black/white images as seen in A “8-bit”. (Panel B)
The images were then inverted meaning the black and white colors were swapped. This
allows the software to measure intensity of cell (now in white) compared to the black
background. In the last adjustment (Panel C), the artifacts were removed using the crop
tool in ImageJ. The resultant “cropped” images are shown in B under “Cropped images”.
(Panel D) Cropped images were measured for area, mean, standard deviation (StdDev),
mode, minimum (Min), maximum (Max), median and % area.
Analysis of the median intensity for all five treatment groups followed the same
protocol outlined for the preliminary test. The median intensity value was calculated to
validate any results from the mean intensity. In the final analysis, the mean intensity
varied from the median, which means artifact inclusion affected the intensity of the
calculated value. Artifact accounts for extreme maximum values and varies the mean, an
average of all pixel intensity. The median accounts for the middle 50% of the values and
is not skewed by extreme values from artifacts such as the mean. A single factor ANOVA
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resulted in a p-value = 0.08; there was no statistical difference between treatment groups,
which could have resulted from a few remaining artifacts in the cropped images.
Measuring the cell diameter resulted in an artifact-free method to compare differences
between treatment groups. For additional discussion and illustration, see Chapter 4,
Figures 4-15 and 4-16.

APPENDIX C
ASTROGLIA REACTIVITY ANALYSIS
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The method used to determine the difference between reactive and non-reactive
astroglia is further explained here. The percent reactive astroglia cell count is used as a
marker for brain damage. Due to many stained cells in the areas analyzed for astroglia
activation, ImageJ software was used to identify and count all cells. A precise soma
diameter for reactive and non-reactive astroglia had to be obtained to increase the
accuracy of this software. The images used for this analysis are seen in Figure C-1.

Figure C-1: Images analyzed for astroglia diameter of the soma. A one-tail t-test was
performed on the data for a P-value of 0.02. The n=12 cells are from four mice.
It was necessary to set cell diameter parameters for the automated identification of
reactive and nonreactive astrocytes. Four images were analyzed to determine the astroglia
diameter of the soma. The TBI-injured and sham-injured sections were compared for
statistical difference. The standard error was used to create the error bars seen in the
graphed data, and the size of reactive and non-reactive cells was averaged for the
histogram found in Chapter 4, Figure 4-16 B. Due to the significant difference between
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TBI and SHAM in the sections from animals bred at Louisiana Tech University, this test
was used to detail the differences between treatment groups.
This identification method utilized 12 reactive and 12 non-reactive astroglia
soma, measured using the line measure tool on ImageJ. Averaging these diameters
determined that a non-reactive diameter was 8.9 ± 2.5 units and a reactive cell diameter
was 31.2 ± 7.8 for this study. The particle size limit was set to 7 to count all the cells, and
the limit was set to 20 to count only reactive cells. All images were visually inspected for
erroneously included/subtracted cells. An astroglia cell count was completed using these
values and the “particle analyzer” on ImageJ. For a thorough discussion of this method,
see Chapter 4. The summary data is presented in Table C-1, and the raw data used for
analysis is presented in Table C-2.
Table C-1: Summary Data
Average
SE

Reactive
31
8

Non-reactive
9
3

Table C-2: Raw Data.
SHAM 189
SHAM 191
TBI 186
TBI 184
Reactive Non- Reactive Non- Reactive Non- Reactive Nonreactive
reactive
reactive
reactive
17
9
31
8
30
7
31
12
32
10
21
8
31
8
33
5
34
14
16
11
46
8
42
6
SE
3.8
2.9
7.6
1.8
8.9
0.3
6.2
3.7
Average 31.3
11.1
23.1
9.1
35.7
7.7
35.1
7.8
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APPENDIX D
POWER ANALYSIS PROTOCOL
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Power Analysis Protocol
The power analysis, discussed in Chapter 6, was performed on median intensity
and percent reactive astroglia in the striatum of GFAP stained mouse sections. A power
analysis determines the sample size that ensures a high probability to reject the null
hypothesis correctly. This process is explained using the median intensity of the external
capsule of the caudate-putamen striatum. It was also repeated for the percent reactive
cells in the same area.
The median intensity for each treatment group and standard deviation of these
groups were calculated in Microsoft Excel with n=3 and five treatment groups. A pooled
standard deviation for all treatment groups was calculated by taking the square root of the
sum of the individual standard deviations squared, divided by the number of treatment
groups (see Eq. D-1).

(Eq. D-1)
Eq. D-1 is the formula for the pooled standard deviation. This formula turns
multiple standard deviations into a single value that can be used in the power analysis.
The calculated values could then be used in the computation for the power analysis using
the open-source software, G*Power 3.1.9.7. The test family for this analysis is
“F tests and the statistical test is ANOVA: Fixed effects, omnibus, one-way.”
The standard deviation and mean values were input into correct regions, and after
all values have been input, the “Effect size F” was calculated using the “calculate”
function on the window (see Figure D-1). Once the values had been transferred to the
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main window, the graphical analysis is “calculated,” and the “X-Y plot for a range of
values” was selected (see Figure D-2).

1.

A

C

2
.

B

F

D
E
G

Figure D-1: How to input values into G*Power software. The values were input (1) in
the software as follows (A) mean values for each treatment group, (B) number of animals
in each treatment groups, (C) number of treatment groups included, (D) n value, (E) a
total number of animals included. In the second panel (F), the “Effect size f” was
calculated by selecting the “calculate” function. All these values were transferred to the
main window (G).

Figure D-2: X/Y plot of power analysis. “Power (1-β err prob)” is selected for the y-axis
“with markers” and “displaying the values in the plot.” The total sample size is 15 (3
animals/5 treatment groups). The increase is set at increments of 5 through to 60.
Increasing by 5 increments (total sample size) shows the resultant power by adding 1
animal/treatment group. The y-axis shows the “power” of sample size, where 0.559 is
equivalent to 55.9 %.
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Power Analysis Results
The power analysis was performed to calculate the number of animals included in
each analysis process to increase the probability of rejecting the null hypothesis. The
analysis was performed on both the median intensity analysis and the percent reactive
astroglia count in the striatum of GFAP stained sagittal mouse brain sections. With the 15
animals (n=3; 5 treatment groups), the median intensity power analysis resulted in a
55.9% probability of rejecting the null hypothesis (see Figure D-3). By adding two
animals to each treatment group, this increases to 89.2%. An acceptable power is 80%,
but by adding three more animals to each treatment group, the resultant power is 95.3%.
Including enough animals to raise the power over 90% increases the chance of
recognizing accurate, distinguishable differences between treatment groups.
The percent reactive astroglia count in the striatum resulted in a statistical
difference between several treatment groups (see Figure D-4). A power analysis of this
data set showed a power of 97.5% with only the 15 animals (n=3; 5 treatment groups).
Adding one animal to each treatment group, the power of the data set is expected to
increase to 99.9% power. A power analysis was also performed on several behavioral test
(Figure D-5). This showed the power as a result of increasing the number of animals in
each treatment groups in rotarod, OF, NOR and EPM. This determined a large increase in
population would be required to increase the power at this time point. As described in the
discussion section, performing the behavioral test closer to the time of injury could result
in a larger distinction between treatment groups and negate the need for a larger sample
size.
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Figure D-3: Median intensity power analysis. The external capsule of the caudateputamen was analyzed for median intensity. With the current sample size (n=3; 5
treatment groups), the probability of rejecting the null hypothesis was 55.9%. Adding one
animal to each treatment group, the probability of rejecting the null hypothesis on this
particular test increased to 76.9%. Adding two animals to each treatment group increases
the power to 89.2%. A power of 80% is acceptable.
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Figure D-4: Reactive cell count of astroglia in the striatum power analysis. This
treatment analysis sample size is 15 animals (n=3; 5 treatment groups), and the power
analysis calculated a 97.5% probability of rejecting the null hypothesis using the 15
animals. The 97.5% probability is an acceptable power, but increasing the number of
animals by one per group would increase the power analysis to 99.9% power.
A power analysis was also performed on the behavioral test for rotarod, OF,
NOR, and EPM. The results of these test indicated little difference between the treatment
groups and the number of animals needed to increase the power was calculated (Figure
D-5). When taken at seven days post-injury, 10 additional mice would be needed to
increase the data set of rotarod and OF to a minimum of 70% power. NOR would require
an additional five mice and EPM would require seven additional mice per treatment
groups to acquire the 70% minimum power. An alternative to adding more mice, as
described in Chapter 6, would be to observe behavioral test at a time closer to the injury
date.
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Figure D-5: Power analysis on the behavioral test performed. The “total number” refers
to the total number of animals in each test. There were 15 mice used for this research (the
consecutive numbers of animals depict the theoretical power). The “N value” refers to the
number of mice per treatment groups, the power for each test is listed with the resultant
increase in total animals. The power of the treatment groups will increase with a drastic
increase in animals.
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